Mml的个人主页 - 老虎社区

Mml

Mml

暂无个人介绍

IP属地：未知

458关注

119粉丝

0主题

0勋章

2021-12-21

Yup

MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

2021-12-21

Hmmm

AMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today

2021-12-19

Hmmm

抱歉，原内容已删除

2021-12-18

Hmmm

抱歉，原内容已删除

2021-12-17

Hmmm

5 Stocks To Watch For December 17, 2021

2021-12-17

Informative

Toplines Before US Market Open on Friday

2021-12-16

Informative

10 Biggest Price Target Changes For Thursday

2021-12-16

Hmmmm

Toplines Before US Market Open on Thursday

2021-12-16

Informative

Shopify rallies after Evercore ISI calls out +25% upside potential

2021-12-16

Informative

Toplines Before US Market Open on Thursday

2021-12-14

Informative

Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.

2021-12-13

Great

Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI

2021-12-11

Hmmm

Sea Ltd stock dropped more than 5% in morning trading

2021-12-09

Good

Rebound Anticipated For Singapore Stock Market

2021-12-08

Hmmm

Pinduoduo shares surged 11% in morning trading

2021-12-07

Good

Intel shares surged more than 7% in after-hours trading

2021-12-06

Hmmm

Singapore Bourse Expected To Remain Rangebound On Monday

2021-12-03

Hmmm

抱歉，原内容已删除

2021-12-02

Informative

Glaxo says its vaccine retains activity against key Omicron mutations

2021-11-29

Oh

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584863771682470","uuid":"3584863771682470","gmtCreate":1622209062843,"gmtModify":1706620618674,"name":"Mml","pinyin":"mml","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":119,"headSize":458,"tweetSize":318,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.39%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":693793472,"gmtCreate":1640074494388,"gmtModify":1640074495552,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Yup","listText":"Yup","text":"Yup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693793472","repostId":"1173202355","repostType":4,"repost":{"id":"1173202355","kind":"news","pubTimestamp":1640053734,"share":"https://www.laohu8.com/m/news/1173202355?lang=&edition=full","pubTime":"2021-12-21 10:28","market":"us","language":"en","title":"MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1173202355","media":"InvestorPlace","summary":"As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omic","content":"<p>As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omicron variant is still casting shadows over markets. This week has started off with mixed news surrounding the companies who are working around the clock to get ahead in the vaccine race. This has been making it difficult for the overall sector to gain the type of momentum it needs for all vaccine stocks to start moving upward. While one company has an encouraging update regarding its vaccine’s effectiveness against the variant, most of its peers haven’t been so lucky.</p>\n<p>What’s Going on With Vaccine Stocks?</p>\n<p>For the companies embedded in the race to beat the variant, this week isn’t off to a good start. Indeed, vaccine stocks are facing noticeable turbulence.<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) began the day with the announcement that a third dose of its Covid-19 vaccine has been proven to&nbsp;increase antibodies against the new variant. Even with such reassuring news, MRNA stock is down 6.25% today. That said, it did cause shares to surge this morning, putting MRNA stock up almost 10% for the week.</p>\n<p>Meanwhile, most of its peers aren’t fairing much better.<b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) just received&nbsp;authorization&nbsp;from the European Union to begin distributing its vaccine throughout Europe during the first half of 2022. While this news sent the stock up in premarket trading today, it hasn’t done much since then. NVAX stock is down more than 7% today. Additionally,&nbsp;<b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) is also falling after an initial&nbsp;early day rise&nbsp;driven by superficial catalysts.</p>\n<p>The only vaccine stock in the green this morning is&nbsp;<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>), which is up more than 2% today despite the&nbsp;recent setback&nbsp;the company experienced regarding its vaccine for children five years old and younger. Meanwhile, Pfizer’s vaccine production partner, Germany-based&nbsp;<b>BioNTech</b>(NASDAQ:<b><u>BNTX</u></b>) is down 4.19% so far, despite the&nbsp;recent news&nbsp;that the two companies will be providing more than 200 million additional vaccine doses to the EU in 2022.</p>\n<p>Why It Matters</p>\n<p>While the week is off to a rough start, every company on this list is still up for the week. The only exception is OCGN, which seems more like a meme stock that is losing momentum.</p>\n<p>However, every other name on this list is fair game for a bullish play on vaccine stocks. The new data from Moderna is highly encouraging, in no small part because it likely means that Pfizer won’t be far behind in tailoring its own vaccine to effectively fight the omicron variant. Novavax’s news is also cause for optimism. While it hasn’t helped the stock rise this morning, it does suggest that global vaccine efforts are moving forward. The same could be said for the recent EU news regarding Pfizer and BioNTech. Novavax has been working hard to gain its place among the vaccine producers that helped us beat the pandemic’s earlier waves. And this looks like an opportunity for it to do exactly that.</p>\n<p>What It Means</p>\n<p>Despite today’s downturn, we will likely see another vaccine stock boom in 2022. Indeed, this will come as companies make real strides against the omicron variant.</p>\n<p>Regardless of exactly how that shakes out, world leaders are going to be working hard to speed up global vaccination efforts to ensure that new variants don’t emerge and complicate matters further. Every stock on this list, with the exception of OCGN, is worth watching as the new year takes shape.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/mrna-nvax-ocgn-pfe-bntx-what-is-going-on-with-vaccine-stocks-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omicron variant is still casting shadows over markets. This week has started off with mixed news ...</p>\n\n<a href=\"https://investorplace.com/2021/12/mrna-nvax-ocgn-pfe-bntx-what-is-going-on-with-vaccine-stocks-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","OCGN":"Ocugen","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/mrna-nvax-ocgn-pfe-bntx-what-is-going-on-with-vaccine-stocks-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173202355","content_text":"As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omicron variant is still casting shadows over markets. This week has started off with mixed news surrounding the companies who are working around the clock to get ahead in the vaccine race. This has been making it difficult for the overall sector to gain the type of momentum it needs for all vaccine stocks to start moving upward. While one company has an encouraging update regarding its vaccine’s effectiveness against the variant, most of its peers haven’t been so lucky.\nWhat’s Going on With Vaccine Stocks?\nFor the companies embedded in the race to beat the variant, this week isn’t off to a good start. Indeed, vaccine stocks are facing noticeable turbulence.Moderna(NASDAQ:MRNA) began the day with the announcement that a third dose of its Covid-19 vaccine has been proven to increase antibodies against the new variant. Even with such reassuring news, MRNA stock is down 6.25% today. That said, it did cause shares to surge this morning, putting MRNA stock up almost 10% for the week.\nMeanwhile, most of its peers aren’t fairing much better.Novavax(NASDAQ:NVAX) just received authorization from the European Union to begin distributing its vaccine throughout Europe during the first half of 2022. While this news sent the stock up in premarket trading today, it hasn’t done much since then. NVAX stock is down more than 7% today. Additionally, Ocugen(NASDAQ:OCGN) is also falling after an initial early day rise driven by superficial catalysts.\nThe only vaccine stock in the green this morning is Pfizer(NYSE:PFE), which is up more than 2% today despite the recent setback the company experienced regarding its vaccine for children five years old and younger. Meanwhile, Pfizer’s vaccine production partner, Germany-based BioNTech(NASDAQ:BNTX) is down 4.19% so far, despite the recent news that the two companies will be providing more than 200 million additional vaccine doses to the EU in 2022.\nWhy It Matters\nWhile the week is off to a rough start, every company on this list is still up for the week. The only exception is OCGN, which seems more like a meme stock that is losing momentum.\nHowever, every other name on this list is fair game for a bullish play on vaccine stocks. The new data from Moderna is highly encouraging, in no small part because it likely means that Pfizer won’t be far behind in tailoring its own vaccine to effectively fight the omicron variant. Novavax’s news is also cause for optimism. While it hasn’t helped the stock rise this morning, it does suggest that global vaccine efforts are moving forward. The same could be said for the recent EU news regarding Pfizer and BioNTech. Novavax has been working hard to gain its place among the vaccine producers that helped us beat the pandemic’s earlier waves. And this looks like an opportunity for it to do exactly that.\nWhat It Means\nDespite today’s downturn, we will likely see another vaccine stock boom in 2022. Indeed, this will come as companies make real strides against the omicron variant.\nRegardless of exactly how that shakes out, world leaders are going to be working hard to speed up global vaccination efforts to ensure that new variants don’t emerge and complicate matters further. Every stock on this list, with the exception of OCGN, is worth watching as the new year takes shape.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693793575,"gmtCreate":1640074461030,"gmtModify":1640074462166,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693793575","repostId":"1158137251","repostType":4,"repost":{"id":"1158137251","kind":"news","pubTimestamp":1640054738,"share":"https://www.laohu8.com/m/news/1158137251?lang=&edition=full","pubTime":"2021-12-21 10:45","market":"us","language":"en","title":"AMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1158137251","media":"InvestorPlace","summary":"Movie theater giant and meme-stock darling AMC Entertainment(NYSE:AMC) has an extra spring in its st","content":"<p>Movie theater giant and meme-stock darling&nbsp;<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>) has an extra spring in its step today.<i>Spider-Man: No Way Home</i>crushed box office expectations — and several attendance records. Despite mounting omicron variant concerns, AMC stock is up 1.99% today after Friday’s 20% leap.</p>\n<p>What else do you need to know about AMC’s web-slinging stock surge?</p>\n<p><i>Spider-Man</i>&nbsp;closed its opening weekend with a bang. The film claimed the biggest December opening of all time, even breaking post-quarantine domestic attendance numbers three times since Friday. When all was said and done, AMC sold more than 7 million tickets from Thursday’s midnight premiere through Sunday. More than 5 million tickets were from U.S. theaters alone. This marks the first time AMC sold at least 1 million tickets each day through a premiere since October 2019. International numbers also enjoyed new highs, setting a new single-day attendance record on Saturday.</p>\n<p>Even trifling through screening options, AMC enjoyed across-the-board boosts from the friendly neighborhood spider. Premium large format (PLF), Dolby Cinema and IMAX each saw elevated screenings this weekend, as it was the biggest weekend ever for AMC Prime.</p>\n<p><i>No Way Home</i>isn’t just unique in its sales numbers: It’s a hyper-modern crypto experiment that may have succeeded. AMC surprised consumers after announcing the giveaway of non-fungible tokens (NFTs) for early buyers of the&nbsp;<i>Spider-Man</i>&nbsp;midnight-release showings. There were a number of conditions to be met to receive the NFT, but roughly 86,000 early birds ended up with a digital item.</p>\n<p>Will the Spidey Upswing Shift AMC Stock Perspectives?</p>\n<p>It’s a bit too early to say whether the NFT promotion served as a boost to movie demand —<i>Spider-Man</i>&nbsp;is practically&nbsp;always a box-office success. Additionally, the film received rave reviews from the jump, earning a 94% aggregate score on review site&nbsp;<i>Rotten Tomatoes</i>.<i>CinemaScore</i>even gave the Marvel film&nbsp;a rare A-plus. As such, the NFT offering clearly didn’t stifle interest in Tom Holland’s latest endeavor, despite it being difficult to definitively attach any causation to the giveaway.</p>\n<p>However, will&nbsp;<i>Spider-Man</i>&nbsp;sling the recently stumbling theater industry back into the spotlight? AMC CEO Adam Aron had some uplifting words for the movie business in lieu of the promising numbers.</p>\n<blockquote>\n “Historically, December is one of the biggest months of the year for major blockbuster releases, so to see SPIDER-MAN: NO WAY HOME set a new all-time opening weekend box office record this month is significant not just for AMC, but for the entire theatrical industry. … We commend our friends at Sony Pictures and Marvel on their wonderfully successful movie, which millions of people have already watched at a U.S. AMC theatre in just 4 days.”\n</blockquote>\n<p>The news brings with it a sigh of relief for the recently struggling movie industry. Only time will tell if&nbsp;<i>Spider-Man</i>&nbsp;marks a resurgence for the star-studded business, but prospects are better than ever.</p>\n<p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/amc-stock-there-are-7-million-reasons-amc-is-on-wall-streets-big-screen-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Movie theater giant and meme-stock darling AMC Entertainment(NYSE:AMC) has an extra spring in its step today.Spider-Man: No Way Homecrushed box office expectations — and several attendance records. ...</p>\n\n<a href=\"https://investorplace.com/2021/12/amc-stock-there-are-7-million-reasons-amc-is-on-wall-streets-big-screen-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://investorplace.com/2021/12/amc-stock-there-are-7-million-reasons-amc-is-on-wall-streets-big-screen-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158137251","content_text":"Movie theater giant and meme-stock darling AMC Entertainment(NYSE:AMC) has an extra spring in its step today.Spider-Man: No Way Homecrushed box office expectations — and several attendance records. Despite mounting omicron variant concerns, AMC stock is up 1.99% today after Friday’s 20% leap.\nWhat else do you need to know about AMC’s web-slinging stock surge?\nSpider-Man closed its opening weekend with a bang. The film claimed the biggest December opening of all time, even breaking post-quarantine domestic attendance numbers three times since Friday. When all was said and done, AMC sold more than 7 million tickets from Thursday’s midnight premiere through Sunday. More than 5 million tickets were from U.S. theaters alone. This marks the first time AMC sold at least 1 million tickets each day through a premiere since October 2019. International numbers also enjoyed new highs, setting a new single-day attendance record on Saturday.\nEven trifling through screening options, AMC enjoyed across-the-board boosts from the friendly neighborhood spider. Premium large format (PLF), Dolby Cinema and IMAX each saw elevated screenings this weekend, as it was the biggest weekend ever for AMC Prime.\nNo Way Homeisn’t just unique in its sales numbers: It’s a hyper-modern crypto experiment that may have succeeded. AMC surprised consumers after announcing the giveaway of non-fungible tokens (NFTs) for early buyers of the Spider-Man midnight-release showings. There were a number of conditions to be met to receive the NFT, but roughly 86,000 early birds ended up with a digital item.\nWill the Spidey Upswing Shift AMC Stock Perspectives?\nIt’s a bit too early to say whether the NFT promotion served as a boost to movie demand —Spider-Man is practically always a box-office success. Additionally, the film received rave reviews from the jump, earning a 94% aggregate score on review site Rotten Tomatoes.CinemaScoreeven gave the Marvel film a rare A-plus. As such, the NFT offering clearly didn’t stifle interest in Tom Holland’s latest endeavor, despite it being difficult to definitively attach any causation to the giveaway.\nHowever, will Spider-Man sling the recently stumbling theater industry back into the spotlight? AMC CEO Adam Aron had some uplifting words for the movie business in lieu of the promising numbers.\n\n “Historically, December is one of the biggest months of the year for major blockbuster releases, so to see SPIDER-MAN: NO WAY HOME set a new all-time opening weekend box office record this month is significant not just for AMC, but for the entire theatrical industry. … We commend our friends at Sony Pictures and Marvel on their wonderfully successful movie, which millions of people have already watched at a U.S. AMC theatre in just 4 days.”\n\nThe news brings with it a sigh of relief for the recently struggling movie industry. Only time will tell if Spider-Man marks a resurgence for the star-studded business, but prospects are better than ever.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693093016,"gmtCreate":1639921042860,"gmtModify":1639921044084,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693093016","repostId":"2192035909","repostType":4,"isVote":1,"tweetType":1,"viewCount":1406,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699244211,"gmtCreate":1639824079138,"gmtModify":1639824080377,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699244211","repostId":"2192754259","repostType":4,"isVote":1,"tweetType":1,"viewCount":1650,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699311815,"gmtCreate":1639748452488,"gmtModify":1639748453638,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699311815","repostId":"1154435289","repostType":4,"repost":{"id":"1154435289","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639733312,"share":"https://www.laohu8.com/m/news/1154435289?lang=&edition=full","pubTime":"2021-12-17 17:28","market":"us","language":"en","title":"5 Stocks To Watch For December 17, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1154435289","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Darden Restaurants, ","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>Darden Restaurants, Inc.</b>&nbsp;to report quarterly earnings at $1.44 per share on revenue of $2.23 billion before the opening bell. Darden Restaurants shares slipped 0.8% to $145.99 in after-hours trading.</li>\n <li><b>FedEx Corporation</b>&nbsp;reported better-than-expected results for its second quarter and boosted its FY22 earnings guidance. The company also reported a $5 billion buyback, including $1.5 billion accelerated buyback program. FedEx shares climbed 4.9% to $250.30 in the after-hours trading session.</li>\n <li>Analysts are expecting&nbsp;<b>Winnebago Industries, Inc.</b>&nbsp;to have earned $2.25 per share on revenue of $1.01 billion for the latest quarter. The company will release earnings before the market open. On Thursday, Winnebago’s board approved a quarterly cash dividend of $0.18 per share. Winnebago shares gained 4.6% to $71.00 in after-hours trading.</li>\n</ul>\n<ul>\n <li><b>Steelcase Inc.</b>&nbsp;reported downbeat results for its third quarter and issued weak sales forecast for the current quarter. Steelcase shares dropped 3.7% to $11.09 in the after-hours trading session.</li>\n <li><b>United States Steel Corporation</b>&nbsp;said it projects adjusted earnings before interest, taxes, depreciation and amortization of around $1.65 billion for the fourth quarter, versus analysts’ estimates of $2.13 billion amid a slowdown in orders. United States Steel shares dropped 5.1% to $22.26 in after-hours trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 17, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 17, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-17 17:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>Darden Restaurants, Inc.</b>&nbsp;to report quarterly earnings at $1.44 per share on revenue of $2.23 billion before the opening bell. Darden Restaurants shares slipped 0.8% to $145.99 in after-hours trading.</li>\n <li><b>FedEx Corporation</b>&nbsp;reported better-than-expected results for its second quarter and boosted its FY22 earnings guidance. The company also reported a $5 billion buyback, including $1.5 billion accelerated buyback program. FedEx shares climbed 4.9% to $250.30 in the after-hours trading session.</li>\n <li>Analysts are expecting&nbsp;<b>Winnebago Industries, Inc.</b>&nbsp;to have earned $2.25 per share on revenue of $1.01 billion for the latest quarter. The company will release earnings before the market open. On Thursday, Winnebago’s board approved a quarterly cash dividend of $0.18 per share. Winnebago shares gained 4.6% to $71.00 in after-hours trading.</li>\n</ul>\n<ul>\n <li><b>Steelcase Inc.</b>&nbsp;reported downbeat results for its third quarter and issued weak sales forecast for the current quarter. Steelcase shares dropped 3.7% to $11.09 in the after-hours trading session.</li>\n <li><b>United States Steel Corporation</b>&nbsp;said it projects adjusted earnings before interest, taxes, depreciation and amortization of around $1.65 billion for the fourth quarter, versus analysts’ estimates of $2.13 billion amid a slowdown in orders. United States Steel shares dropped 5.1% to $22.26 in after-hours trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WGO":"温尼巴格实业","SCS":"Steelcase Inc.","FDX":"联邦快递","DRI":"达登饭店","X":"美国钢铁"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154435289","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Darden Restaurants, Inc. to report quarterly earnings at $1.44 per share on revenue of $2.23 billion before the opening bell. Darden Restaurants shares slipped 0.8% to $145.99 in after-hours trading.\nFedEx Corporation reported better-than-expected results for its second quarter and boosted its FY22 earnings guidance. The company also reported a $5 billion buyback, including $1.5 billion accelerated buyback program. FedEx shares climbed 4.9% to $250.30 in the after-hours trading session.\nAnalysts are expecting Winnebago Industries, Inc. to have earned $2.25 per share on revenue of $1.01 billion for the latest quarter. The company will release earnings before the market open. On Thursday, Winnebago’s board approved a quarterly cash dividend of $0.18 per share. Winnebago shares gained 4.6% to $71.00 in after-hours trading.\n\n\nSteelcase Inc. reported downbeat results for its third quarter and issued weak sales forecast for the current quarter. Steelcase shares dropped 3.7% to $11.09 in the after-hours trading session.\nUnited States Steel Corporation said it projects adjusted earnings before interest, taxes, depreciation and amortization of around $1.65 billion for the fourth quarter, versus analysts’ estimates of $2.13 billion amid a slowdown in orders. United States Steel shares dropped 5.1% to $22.26 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699335292,"gmtCreate":1639747930518,"gmtModify":1639747931645,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699335292","repostId":"1138605449","repostType":4,"repost":{"id":"1138605449","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639746084,"share":"https://www.laohu8.com/m/news/1138605449?lang=&edition=full","pubTime":"2021-12-17 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1138605449","media":"Tiger Newspress","summary":"U.S. Stock futures headed for a lower open Friday morning after a rout in technology stocks during T","content":"<p>U.S.&nbsp;Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&amp;P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.<img src=\"https://static.tigerbbs.com/120d112226a9ec4591babf844729ca58\" tg-width=\"1080\" tg-height=\"376\" width=\"100%\" height=\"auto\">Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed&nbsp;could hike interest rates three times next year.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DRI\">Darden Restaurants</a></b> – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/WGO\">Winnebago</a></b> – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.</p>\n<p><b><a href=\"https://laohu8.com/S/FDX\">FedEx</a></b> – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/EPAY\">Bottomline</a></b> – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that&nbsp;Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> – <b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> shares fell 2.1% in the premarket after the CDC recommended that adults receive the&nbsp;Pfizer(PFE) or&nbsp;Moderna(MRNA) Covid-19 vaccines rather than the J&amp;J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.</p>\n<p><b><a href=\"https://laohu8.com/S/AFRM\">Affirm Holdings, Inc.</a></b> – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.</p>\n<p><b><a href=\"https://laohu8.com/S/X\">U.S. Steel</a></b> – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.</p>\n<p><b><a href=\"https://laohu8.com/S/SCS\">Steelcase</a></b> – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S.&nbsp;Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&amp;P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.<img src=\"https://static.tigerbbs.com/120d112226a9ec4591babf844729ca58\" tg-width=\"1080\" tg-height=\"376\" width=\"100%\" height=\"auto\">Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed&nbsp;could hike interest rates three times next year.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DRI\">Darden Restaurants</a></b> – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/WGO\">Winnebago</a></b> – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.</p>\n<p><b><a href=\"https://laohu8.com/S/FDX\">FedEx</a></b> – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/EPAY\">Bottomline</a></b> – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that&nbsp;Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> – <b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> shares fell 2.1% in the premarket after the CDC recommended that adults receive the&nbsp;Pfizer(PFE) or&nbsp;Moderna(MRNA) Covid-19 vaccines rather than the J&amp;J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.</p>\n<p><b><a href=\"https://laohu8.com/S/AFRM\">Affirm Holdings, Inc.</a></b> – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.</p>\n<p><b><a href=\"https://laohu8.com/S/X\">U.S. Steel</a></b> – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.</p>\n<p><b><a href=\"https://laohu8.com/S/SCS\">Steelcase</a></b> – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138605449","content_text":"U.S. Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.\nAt 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed could hike interest rates three times next year.\nStocks making the biggest moves premarket: \nDarden Restaurants – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.\nWinnebago – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.\nFedEx – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.\nRivian Automotive, Inc. – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.\nBottomline – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.\nCerner – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.\nJohnson & Johnson – Johnson & Johnson shares fell 2.1% in the premarket after the CDC recommended that adults receive the Pfizer(PFE) or Moderna(MRNA) Covid-19 vaccines rather than the J&J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.\nAffirm Holdings, Inc. – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.\nNovavax – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.\nU.S. Steel – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.\nSteelcase – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690605469,"gmtCreate":1639660809729,"gmtModify":1639660810880,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690605469","repostId":"1191683541","repostType":4,"repost":{"id":"1191683541","kind":"news","pubTimestamp":1639658241,"share":"https://www.laohu8.com/m/news/1191683541?lang=&edition=full","pubTime":"2021-12-16 20:37","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1191683541","media":"Benzinga","summary":"Stifel cut the price target on Under Armour, Inc.. from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.RBC Capital lowered the price target on Airbnb, Inc. from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.Morgan Stanley lowered DocuSign, Inc. price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.Barclays cut the price target on Aptiv PLC from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market","content":"<ul>\n <li>Stifel cut the price target on&nbsp;<b>Under Armour, Inc..</b>(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.</li>\n <li>RBC Capital lowered the price target on&nbsp;<b>Airbnb, Inc.</b>(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.</li>\n <li>Morgan Stanley cut&nbsp;<b>AT&amp;T Inc.</b>(NYSE:T) price target from $32 to $28. AT&amp;T shares rose 1.7% to $22.55 in pre-market trading.</li>\n <li>Morgan Stanley lowered&nbsp;<b>DocuSign, Inc.</b>(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.</li>\n <li>Barclays cut the price target on&nbsp;<b>Aptiv PLC</b>(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.</li>\n <li>Raymond James raised&nbsp;<b>The Progressive Corporation</b>(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Magna International Inc.</b>(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.</li>\n <li>B of A Securities reduced the price target for&nbsp;<b>Wayfair Inc.</b>(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. cut&nbsp;<b>IGM Biosciences, Inc.</b>(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.</li>\n <li>Needham cut&nbsp;<b>Medtronic plc</b>(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign","T":"美国电话电报","ABNB":"爱彼迎"},"source_url":"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191683541","content_text":"Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.\nMorgan Stanley cut AT&T Inc.(NYSE:T) price target from $32 to $28. AT&T shares rose 1.7% to $22.55 in pre-market trading.\nMorgan Stanley lowered DocuSign, Inc.(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.\nBarclays cut the price target on Aptiv PLC(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.\nRaymond James raised The Progressive Corporation(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.\nWells Fargo boosted the price target for Magna International Inc.(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.\nB of A Securities reduced the price target for Wayfair Inc.(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.\nHC Wainwright & Co. cut IGM Biosciences, Inc.(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.\nNeedham cut Medtronic plc(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690608287,"gmtCreate":1639660378795,"gmtModify":1639660378795,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690608287","repostId":"1142996286","repostType":4,"repost":{"id":"1142996286","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639659703,"share":"https://www.laohu8.com/m/news/1142996286?lang=&edition=full","pubTime":"2021-12-16 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1142996286","media":"Tiger Newspress","summary":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.$Delta Air Lines$ – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-","content":"<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p>\n<p><b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p>\n<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p>\n<p><b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p>\n<p><b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p>\n<p><b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p>\n<p><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p>\n<p><b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p>\n<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p>\n<p><b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p>\n<p><b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p>\n<p><b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p>\n<p><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142996286","content_text":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.\nAt 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.With the Fed giving markets a breather Wednesday, traders will turn their Thursday to fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after last’s 52-week low.\nStocks making the biggest moves premarket: \nDelta Air Lines – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.\nAccenture PLC – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.\nRegeneron Pharmaceuticals – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.\nLennar – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.\nNovartis AG – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.\nVisa – Visa rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.\nSmucker's – Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.\nIntuitive Surgical – Intuitive Surgical was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.\nAT&T Inc – Morgan Stanley upgraded AT&T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&T gained 1.5% in premarket trading.\nPetco Health and Wellness Company, Inc. – The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.\nShopify – The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1777,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690603041,"gmtCreate":1639660187421,"gmtModify":1639660188515,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690603041","repostId":"1122700546","repostType":4,"repost":{"id":"1122700546","kind":"news","pubTimestamp":1639656448,"share":"https://www.laohu8.com/m/news/1122700546?lang=&edition=full","pubTime":"2021-12-16 20:07","market":"us","language":"en","title":"Shopify rallies after Evercore ISI calls out +25% upside potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1122700546","media":"Seeking Alpha","summary":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.","content":"<ul>\n <li>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.</li>\n <li>Analyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.</li>\n <li>Shares of SHOP are&nbsp;up 3.08%&nbsp;in premarket action to $1,410.26.</li>\n <li>Evercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the&nbsp;average Wall Street PT of $1,698.19.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shopify rallies after Evercore ISI calls out +25% upside potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShopify rallies after Evercore ISI calls out +25% upside potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/...</p>\n\n<a href=\"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122700546","content_text":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.\nShares of SHOP are up 3.08% in premarket action to $1,410.26.\nEvercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the average Wall Street PT of $1,698.19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1806,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690609850,"gmtCreate":1639660136423,"gmtModify":1639660137549,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690609850","repostId":"1142996286","repostType":4,"repost":{"id":"1142996286","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639659703,"share":"https://www.laohu8.com/m/news/1142996286?lang=&edition=full","pubTime":"2021-12-16 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1142996286","media":"Tiger Newspress","summary":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.$Delta Air Lines$ – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-","content":"<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p>\n<p><b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p>\n<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p>\n<p><b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p>\n<p><b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p>\n<p><b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p>\n<p><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p>\n<p><b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p>\n<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p>\n<p><b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p>\n<p><b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p>\n<p><b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p>\n<p><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142996286","content_text":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.\nAt 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.With the Fed giving markets a breather Wednesday, traders will turn their Thursday to fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after last’s 52-week low.\nStocks making the biggest moves premarket: \nDelta Air Lines – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.\nAccenture PLC – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.\nRegeneron Pharmaceuticals – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.\nLennar – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.\nNovartis AG – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.\nVisa – Visa rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.\nSmucker's – Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.\nIntuitive Surgical – Intuitive Surgical was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.\nAT&T Inc – Morgan Stanley upgraded AT&T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&T gained 1.5% in premarket trading.\nPetco Health and Wellness Company, Inc. – The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.\nShopify – The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1371,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607919238,"gmtCreate":1639472743238,"gmtModify":1639472744343,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607919238","repostId":"1114636896","repostType":4,"repost":{"id":"1114636896","kind":"news","pubTimestamp":1639439509,"share":"https://www.laohu8.com/m/news/1114636896?lang=&edition=full","pubTime":"2021-12-14 07:51","market":"us","language":"en","title":"Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.","url":"https://stock-news.laohu8.com/highlight/detail?id=1114636896","media":"Barrons","summary":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is ","content":"<p>Shares of electric-vehicle leader&nbsp;Tesla&nbsp;crossed into bear-market territory&nbsp;today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.</p>\n<p>Tesla (ticker: TSLA) stock closed down 5% at $966.41. The&nbsp;S&amp;P 500 index&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;both closed down 0.9%.</p>\n<p>The Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.</p>\n<p>Whether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.</p>\n<p>Whether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.</p>\n<p>One of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, <i>Barron’s</i> wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.</p>\n<p>Back then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.</p>\n<p>That would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.</p>\n<p>With all that coming, it raising the question of why the shares are struggling.</p>\n<p>Two things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.</p>\n<p>Second, there is the issue of Musk being named Time’s Person of the Year.Amazon.com&nbsp;(AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.</p>\n<p>The Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.</p>\n<p>Still, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 07:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114636896","content_text":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.\nTesla (ticker: TSLA) stock closed down 5% at $966.41. The S&P 500 index and Dow Jones Industrial Average both closed down 0.9%.\nThe Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.\nWhether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.\nWhether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.\nOne of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, Barron’s wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.\nBack then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.\nThat would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.\nWith all that coming, it raising the question of why the shares are struggling.\nTwo things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.\nSecond, there is the issue of Musk being named Time’s Person of the Year.Amazon.com (AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.\nThe Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.\nStill, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.","news_type":1},"isVote":1,"tweetType":1,"viewCount":628,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604284528,"gmtCreate":1639403527473,"gmtModify":1639403980729,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604284528","repostId":"1101330061","repostType":4,"repost":{"id":"1101330061","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639402663,"share":"https://www.laohu8.com/m/news/1101330061?lang=&edition=full","pubTime":"2021-12-13 21:37","market":"us","language":"en","title":"Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI","url":"https://stock-news.laohu8.com/highlight/detail?id=1101330061","media":"Tiger Newspress","summary":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today ann","content":"<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VERU":"Veru Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101330061","content_text":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).\nENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605640297,"gmtCreate":1639160477225,"gmtModify":1639160478352,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605640297","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://www.laohu8.com/m/news/1133027099?lang=&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-11 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602877662,"gmtCreate":1639010952150,"gmtModify":1639010953069,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602877662","repostId":"1192089081","repostType":4,"repost":{"id":"1192089081","kind":"news","pubTimestamp":1639008258,"share":"https://www.laohu8.com/m/news/1192089081?lang=&edition=full","pubTime":"2021-12-09 08:04","market":"sg","language":"en","title":"Rebound Anticipated For Singapore Stock Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1192089081","media":"RTTNews","summary":"The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point plateau although it may tick higher again on Thursday.The global forecast for the Asian markets is cautiously optimistic, again supported by oil and technology companies. The European markets were down and the U.S. bourses were up and the Asian markets figure to follow the latter lead.The STI finished","content":"<p>The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point plateau although it may tick higher again on Thursday.</p>\n<p>The global forecast for the Asian markets is cautiously optimistic, again supported by oil and technology companies. The European markets were down and the U.S. bourses were up and the Asian markets figure to follow the latter lead.</p>\n<p>The STI finished slightly lower on Wednesday following mixed performances from the financial shares and industrial stocks.</p>\n<p>For the day, the index dipped 4.89 points or 0.16 percent to finish at 3,129.77 after trading between 3,124.31 and 3,140.75. Volume was 1.11 billion shares worth 1.04 billion Singapore dollars. There were 223 gainers and 202 decliners.</p>\n<p>Among the actives, CapitaLand Integrated Commercial Trust sank 0.49 percent, while City Developments was up 0.14 percent, Comfort DelGro retreated 0.71 percent, DBS Group dipped 0.22 percent, Genting Singapore added 0.65 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation fell 0.26 percent, SATS tanked 1.27 percent, SembCorp Industries tumbled 1.00 percent, Singapore Airlines gained 0.40 percent, Singapore Exchange declined 0.95 percent, Singapore Press Holdings lost 0.43 percent, Singapore Technologies Engineering skidded 0.53 percent, SingTel jumped 1.24 percent, United Overseas Bank collected 0.41 percent, Wilmar International dropped 0.48 percent, Yangzijiang Shipbuilding plunged 1.52 percent and Dairy Farm International, Mapletree Commercial Trust, Mapletree Logistics Trust, Ascendas REIT and Thai Beverage were unchanged.</p>\n<p>The lead from Wall Street is positive as the major averages opened mixed on Wednesday, shook off a midday slump and finished in the green.</p>\n<p>The Dow added 35.32 points or 0.10 percent to finish at 35,754.75, while the NASDAQ jumped 100.07 points or 0.64 percent to end at 15,786.99 and the S&amp;P 500 rose 14.46 points or 0.31 percent to close at 4,701.21.</p>\n<p>The choppy trading seen for most of the day came as traders expressed some uncertainty about the near-term outlook for the markets following recent volatility.</p>\n<p>With concerns about the impact of the Omicron variant easing, traders are now looking ahead to next week's Federal Reserve's monetary policy announcement. Reports suggest the Fed could decide to double the pace of tapering its asset purchase program to $30 billion per month.</p>\n<p>Some positive sentiment was generated by comments from Pfizer (PFE) and BioNTech (BNTX) regarding the effectiveness of their Covid vaccine as preliminary laboratory studies have demonstrated that three doses of their vaccine neutralize the Omicron variant.</p>\n<p>Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) reported a drop in U.S. crude inventories last week. West Texas Intermediate Crude oil futures for January ended higher by $0.31 or 0.4 percent at $72.36 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rebound Anticipated For Singapore Stock Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRebound Anticipated For Singapore Stock Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 08:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3247905/rebound-anticipated-for-singapore-stock-market.aspx?type=acom><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point ...</p>\n\n<a href=\"https://www.rttnews.com/3247905/rebound-anticipated-for-singapore-stock-market.aspx?type=acom\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3247905/rebound-anticipated-for-singapore-stock-market.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192089081","content_text":"The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point plateau although it may tick higher again on Thursday.\nThe global forecast for the Asian markets is cautiously optimistic, again supported by oil and technology companies. The European markets were down and the U.S. bourses were up and the Asian markets figure to follow the latter lead.\nThe STI finished slightly lower on Wednesday following mixed performances from the financial shares and industrial stocks.\nFor the day, the index dipped 4.89 points or 0.16 percent to finish at 3,129.77 after trading between 3,124.31 and 3,140.75. Volume was 1.11 billion shares worth 1.04 billion Singapore dollars. There were 223 gainers and 202 decliners.\nAmong the actives, CapitaLand Integrated Commercial Trust sank 0.49 percent, while City Developments was up 0.14 percent, Comfort DelGro retreated 0.71 percent, DBS Group dipped 0.22 percent, Genting Singapore added 0.65 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation fell 0.26 percent, SATS tanked 1.27 percent, SembCorp Industries tumbled 1.00 percent, Singapore Airlines gained 0.40 percent, Singapore Exchange declined 0.95 percent, Singapore Press Holdings lost 0.43 percent, Singapore Technologies Engineering skidded 0.53 percent, SingTel jumped 1.24 percent, United Overseas Bank collected 0.41 percent, Wilmar International dropped 0.48 percent, Yangzijiang Shipbuilding plunged 1.52 percent and Dairy Farm International, Mapletree Commercial Trust, Mapletree Logistics Trust, Ascendas REIT and Thai Beverage were unchanged.\nThe lead from Wall Street is positive as the major averages opened mixed on Wednesday, shook off a midday slump and finished in the green.\nThe Dow added 35.32 points or 0.10 percent to finish at 35,754.75, while the NASDAQ jumped 100.07 points or 0.64 percent to end at 15,786.99 and the S&P 500 rose 14.46 points or 0.31 percent to close at 4,701.21.\nThe choppy trading seen for most of the day came as traders expressed some uncertainty about the near-term outlook for the markets following recent volatility.\nWith concerns about the impact of the Omicron variant easing, traders are now looking ahead to next week's Federal Reserve's monetary policy announcement. Reports suggest the Fed could decide to double the pace of tapering its asset purchase program to $30 billion per month.\nSome positive sentiment was generated by comments from Pfizer (PFE) and BioNTech (BNTX) regarding the effectiveness of their Covid vaccine as preliminary laboratory studies have demonstrated that three doses of their vaccine neutralize the Omicron variant.\nCrude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) reported a drop in U.S. crude inventories last week. West Texas Intermediate Crude oil futures for January ended higher by $0.31 or 0.4 percent at $72.36 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606465004,"gmtCreate":1638921201264,"gmtModify":1638921202238,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606465004","repostId":"1142645155","repostType":4,"repost":{"id":"1142645155","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638890012,"share":"https://www.laohu8.com/m/news/1142645155?lang=&edition=full","pubTime":"2021-12-07 23:13","market":"us","language":"en","title":"Pinduoduo shares surged 11% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142645155","media":"Tiger Newspress","summary":"Pinduoduo shares surged 11% in morning trading after Macquarie gave pinduoduo a market beating ratin","content":"<p>Pinduoduo shares surged 11% in morning trading&nbsp;after&nbsp;Macquarie gave pinduoduo a market beating rating with a target price of $95.</p>\n<p><img src=\"https://static.tigerbbs.com/38c15dca491bd8741f8ac3af099bdeb7\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinduoduo shares surged 11% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinduoduo shares surged 11% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 23:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pinduoduo shares surged 11% in morning trading&nbsp;after&nbsp;Macquarie gave pinduoduo a market beating rating with a target price of $95.</p>\n<p><img src=\"https://static.tigerbbs.com/38c15dca491bd8741f8ac3af099bdeb7\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142645155","content_text":"Pinduoduo shares surged 11% in morning trading after Macquarie gave pinduoduo a market beating rating with a target price of $95.","news_type":1},"isVote":1,"tweetType":1,"viewCount":576,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606185457,"gmtCreate":1638843254914,"gmtModify":1638843255865,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606185457","repostId":"1133458146","repostType":4,"repost":{"id":"1133458146","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638837591,"share":"https://www.laohu8.com/m/news/1133458146?lang=&edition=full","pubTime":"2021-12-07 08:39","market":"us","language":"en","title":"Intel shares surged more than 7% in after-hours trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133458146","media":"Tiger Newspress","summary":"Intel shares surged more than 7% in after-hours trading.Intel Corp is planning to publicly list shar","content":"<p>Intel&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;after-hours&nbsp;trading.<img src=\"https://static.tigerbbs.com/6646a6cbd4f0e04c695a379c7768d260\" tg-width=\"735\" tg-height=\"649\" width=\"100%\" height=\"auto\">Intel Corp&nbsp;is planning to publicly list shares in its self-driving-car unit <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a>, which could value the unit at north of $50 billion ,the Wall Street Journal reported on Monday, citing people familiar with the matter.</p>\n<p>However, there are no guarantees Intel will ultimately follow through with an offering, the report said&nbsp;adding that the announcement is expected as soon as this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel shares surged more than 7% in after-hours trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel shares surged more than 7% in after-hours trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 08:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intel&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;after-hours&nbsp;trading.<img src=\"https://static.tigerbbs.com/6646a6cbd4f0e04c695a379c7768d260\" tg-width=\"735\" tg-height=\"649\" width=\"100%\" height=\"auto\">Intel Corp&nbsp;is planning to publicly list shares in its self-driving-car unit <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a>, which could value the unit at north of $50 billion ,the Wall Street Journal reported on Monday, citing people familiar with the matter.</p>\n<p>However, there are no guarantees Intel will ultimately follow through with an offering, the report said&nbsp;adding that the announcement is expected as soon as this week.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133458146","content_text":"Intel shares surged more than 7% in after-hours trading.Intel Corp is planning to publicly list shares in its self-driving-car unit Mobileye, which could value the unit at north of $50 billion ,the Wall Street Journal reported on Monday, citing people familiar with the matter.\nHowever, there are no guarantees Intel will ultimately follow through with an offering, the report said adding that the announcement is expected as soon as this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608448102,"gmtCreate":1638783361438,"gmtModify":1638783366193,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608448102","repostId":"1178940634","repostType":4,"repost":{"id":"1178940634","kind":"news","pubTimestamp":1638748983,"share":"https://www.laohu8.com/m/news/1178940634?lang=&edition=full","pubTime":"2021-12-06 08:03","market":"sg","language":"en","title":"Singapore Bourse Expected To Remain Rangebound On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1178940634","media":"RTTNews","summary":"The Singapore stock market has moved higher in two of three trading days since the end of the six-da","content":"<p>The Singapore stock market has moved higher in two of three trading days since the end of the six-day losing streak in which it had plummeted almost 200 points or 6.4 percent. The Straits Times Index now sits just above the 3,100-point plateau although it's expected to turn lower again on Monday.</p>\n<p></p>\n<p>The global forecast for the Asian markets is negative on coronavirus and economic concerns, with oil and technology stocks likely to lead the way lower. The European and U.S. markets finished solidly under water and the Asian markets are expected to open in similar fashion.</p>\n<p></p>\n<p>The STI finished modestly higher on Friday following gains from the industrials and properties, while the financials were mixed.</p>\n<p></p>\n<p>For the day, the index rose 9.82 points or 0.32 percent to finish at 3,101.93 after trading between 3,080.29 and 3,109.64. Volume was 1.04 billion shares worth 1.13 billion Singapore dollars. There were 269 gainers and 194 decliners.</p>\n<p></p>\n<p>Among the actives, Ascendas REIT added 0.68 percent, while CapitaLand Integrated Commercial Trust shed 0.48 percent, City Developments and Wilmar International both advanced 0.74 percent, Comfort DelGro accelerated 2.19 percent, Dairy Farm International and Genting Singapore both jumped 2.01 percent, DBS Group lost 0.25 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation eased 0.09 percent, SATS surged 2.62 percent, SembCorp Industries soared 2.58 percent, Singapore Airlines gained 0.62 percent, Singapore Exchange spiked 2.43 percent, Singapore Technologies Engineering increased 0.27 percent, Thai Beverage rallied 0.76 percent, United Overseas Bank collected 0.46 percent, Yangzijiang Shipbuilding climbed 0.78 percent and Mapletree Commercial Trust, Mapletree Logistics Trust, Singapore Press Holdings and SingTel were unchanged.</p>\n<p></p>\n<p>The lead from Wall Street is soft as the major averages opened slightly higher on Friday but quickly turned lower and spent the remainder of the day in negative territory.</p>\n<p></p>\n<p>The Dow shed 59/72 points or 0.17 percent to finish at 34,580.08, while the NASDAQ plummeted 295.83 points or 1.92 percent to close at 15,085.47 and the S&amp;P 500 lost 38.67 points or 0.84 percent to end at 4,538.43. For the week, the NASDAQ tumbled 2.6 percent, the S&amp;P lost 1.2 percent and the Dow fell 0.9 percent.</p>\n<p></p>\n<p>The losses extended the volatility seen throughout the week, with stocks showing wild swings in reaction to the Omicron variant of the coronavirus. After the first confirmed case in the U.S. earlier in the week, the new variant has now been detected in at least five states.</p>\n<p></p>\n<p>Traders also reacted to the Labor Department report showing weaker than expected U.S. job growth in November, although the jobless rate fell to 4.2 percent - its lowest since February 2020.</p>\n<p></p>\n<p>While the disappointing job growth has raised some concerns about the economic outlook amid the emergence of the Omicron variant, the Federal Reserve is not expected to deviate from accelerating the tapering of its asset purchases.</p>\n<p></p>\n<p>Crude oil futures pared early gains and settled lower Friday amid uncertainty about the outlook for energy demand due to fresh restrictions following the spread of the new coronavirus variant Omicron in several countries. West Texas Intermediate Crude oil futures for January ended down by $0.24 or 0.4 percent at $66.26 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Bourse Expected To Remain Rangebound On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Bourse Expected To Remain Rangebound On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 08:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3246867/singapore-bourse-expected-to-remain-rangebound-on-monday.aspx?type=acom><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market has moved higher in two of three trading days since the end of the six-day losing streak in which it had plummeted almost 200 points or 6.4 percent. The Straits Times Index ...</p>\n\n<a href=\"https://www.rttnews.com/3246867/singapore-bourse-expected-to-remain-rangebound-on-monday.aspx?type=acom\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3246867/singapore-bourse-expected-to-remain-rangebound-on-monday.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178940634","content_text":"The Singapore stock market has moved higher in two of three trading days since the end of the six-day losing streak in which it had plummeted almost 200 points or 6.4 percent. The Straits Times Index now sits just above the 3,100-point plateau although it's expected to turn lower again on Monday.\n\nThe global forecast for the Asian markets is negative on coronavirus and economic concerns, with oil and technology stocks likely to lead the way lower. The European and U.S. markets finished solidly under water and the Asian markets are expected to open in similar fashion.\n\nThe STI finished modestly higher on Friday following gains from the industrials and properties, while the financials were mixed.\n\nFor the day, the index rose 9.82 points or 0.32 percent to finish at 3,101.93 after trading between 3,080.29 and 3,109.64. Volume was 1.04 billion shares worth 1.13 billion Singapore dollars. There were 269 gainers and 194 decliners.\n\nAmong the actives, Ascendas REIT added 0.68 percent, while CapitaLand Integrated Commercial Trust shed 0.48 percent, City Developments and Wilmar International both advanced 0.74 percent, Comfort DelGro accelerated 2.19 percent, Dairy Farm International and Genting Singapore both jumped 2.01 percent, DBS Group lost 0.25 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation eased 0.09 percent, SATS surged 2.62 percent, SembCorp Industries soared 2.58 percent, Singapore Airlines gained 0.62 percent, Singapore Exchange spiked 2.43 percent, Singapore Technologies Engineering increased 0.27 percent, Thai Beverage rallied 0.76 percent, United Overseas Bank collected 0.46 percent, Yangzijiang Shipbuilding climbed 0.78 percent and Mapletree Commercial Trust, Mapletree Logistics Trust, Singapore Press Holdings and SingTel were unchanged.\n\nThe lead from Wall Street is soft as the major averages opened slightly higher on Friday but quickly turned lower and spent the remainder of the day in negative territory.\n\nThe Dow shed 59/72 points or 0.17 percent to finish at 34,580.08, while the NASDAQ plummeted 295.83 points or 1.92 percent to close at 15,085.47 and the S&P 500 lost 38.67 points or 0.84 percent to end at 4,538.43. For the week, the NASDAQ tumbled 2.6 percent, the S&P lost 1.2 percent and the Dow fell 0.9 percent.\n\nThe losses extended the volatility seen throughout the week, with stocks showing wild swings in reaction to the Omicron variant of the coronavirus. After the first confirmed case in the U.S. earlier in the week, the new variant has now been detected in at least five states.\n\nTraders also reacted to the Labor Department report showing weaker than expected U.S. job growth in November, although the jobless rate fell to 4.2 percent - its lowest since February 2020.\n\nWhile the disappointing job growth has raised some concerns about the economic outlook amid the emergence of the Omicron variant, the Federal Reserve is not expected to deviate from accelerating the tapering of its asset purchases.\n\nCrude oil futures pared early gains and settled lower Friday amid uncertainty about the outlook for energy demand due to fresh restrictions following the spread of the new coronavirus variant Omicron in several countries. West Texas Intermediate Crude oil futures for January ended down by $0.24 or 0.4 percent at $66.26 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":705,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601390339,"gmtCreate":1638489328116,"gmtModify":1638489328586,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601390339","repostId":"2188548587","repostType":4,"isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603520446,"gmtCreate":1638429891300,"gmtModify":1638429904315,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603520446","repostId":"1197973971","repostType":4,"repost":{"id":"1197973971","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638429281,"share":"https://www.laohu8.com/m/news/1197973971?lang=&edition=full","pubTime":"2021-12-02 15:14","market":"us","language":"en","title":"Glaxo says its vaccine retains activity against key Omicron mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973971","media":"Tiger Newspress","summary":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint ser","content":"<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo says its vaccine retains activity against key Omicron mutations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo says its vaccine retains activity against key Omicron mutations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197973971","content_text":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.\nGeorge Scangos, PhD, Chief Executive Officer of Vir, said:“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”\nDr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”\nAbout sotrovimab\nSotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.\nUpdated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).\nAbout the sotrovimab clinical development programme\n\nCOMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published inThe New England Journal of Medicineon 27 October 2021 and final data were pre-published on 8 November 2021 onmedRxiv.\nCOMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.\nCOMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.\nGSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.\n\nAbout global access to sotrovimab\n\nSotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.\nGSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe\nCOVID-19.\nSotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.\n\nSotrovimab in the United States\nThe following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.\nSotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.\nSotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nAuthorized Use\nThe U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\nLimitations of Authorized Use\nSotrovimab is not authorized for use in patients:\n\nwho are hospitalized due to COVID-19, OR\nwho require oxygen therapy due to COVID-19, OR\nwho require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)\n\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.\nImportant Safety Information\nCONTRAINDICATIONS\nSotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.\nWARNINGS AND PRECAUTIONS\nThere are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.\nHypersensitivity Including Anaphylaxis and Infusion-Related Reactions\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.\nInfusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.\nSigns and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.\nConsider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.\nHypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.\nClinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration\nClinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.\nLimitations of Benefit and Potential for Risk in Patients with Severe COVID‑19\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.\nADVERSE EVENTS\nHypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.\nThe most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.\nUSE IN SPECIFIC POPULATIONS\nPregnancy\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\nLactation\nThere are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.\nAbout the GSK and Vir collaboration\nIn April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.\nGSK commitment to tackling COVID-19\nGSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.\nGSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.\nGSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.\nGSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.\nVir’s commitment to COVID-19\nVir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600405958,"gmtCreate":1638182154411,"gmtModify":1638182155906,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600405958","repostId":"1173411638","repostType":4,"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":144089370,"gmtCreate":1626253290890,"gmtModify":1633928611257,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>How? To hold?","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>How? To hold?","text":"$AMC Entertainment(AMC)$How? To hold?","images":[{"img":"https://static.tigerbbs.com/68ec9d50d23be635a4ea0891896b4d18","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/144089370","isVote":1,"tweetType":1,"viewCount":737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":808197255,"gmtCreate":1627563478877,"gmtModify":1633763783330,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/808197255","repostId":"1122445859","repostType":4,"isVote":1,"tweetType":1,"viewCount":184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":842704456,"gmtCreate":1636241652933,"gmtModify":1636241654329,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/842704456","repostId":"2181374735","repostType":4,"isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876509944,"gmtCreate":1637327756316,"gmtModify":1637327776139,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/876509944","repostId":"1138047553","repostType":4,"repost":{"id":"1138047553","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872874197,"gmtCreate":1637492364994,"gmtModify":1637492365418,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"I dun believe it","listText":"I dun believe it","text":"I dun believe it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872874197","repostId":"2184782893","repostType":4,"isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":830240782,"gmtCreate":1629077726146,"gmtModify":1633687590664,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/830240782","repostId":"1129589874","repostType":4,"repost":{"id":"1129589874","kind":"news","pubTimestamp":1629067868,"share":"https://www.laohu8.com/m/news/1129589874?lang=&edition=full","pubTime":"2021-08-16 06:51","market":"us","language":"en","title":"Nvidia, Tencent,Walmart, Target and Other Stocks to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1129589874","media":"Barrons","summary":"It’s the late innings of second-quarter earnings season, with retailers ready to step up to the plate. Walmart and Home Depot report on Tuesday, followed by Lowe’s, Target, and TJX on Wednesday. Kohl’s, Macy’s, BJ’s Wholesale, and L Brands are Thursday’s retail highlights, then Foot Locker closes the week on Friday.The Census Bureau’s July retail sales data for July is also out this week, on Tuesday. Economists on average are forecasting a 0.2% seasonally adjusted increase last month, after a 0.","content":"<p>It’s the late innings of second-quarter earnings season, with retailers ready to step up to the plate. Walmart and Home Depot report on Tuesday, followed by Lowe’s, Target, and TJX on Wednesday.&nbsp;Kohl’s, Macy’s, BJ’s Wholesale, and L Brands are Thursday’s retail highlights, then Foot Locker closes the week on Friday.</p>\n<p>The Census Bureau’s July retail sales data for July is also out this week, on Tuesday. Economists on average are forecasting a&nbsp;0.2% seasonally adjusted increase last month, after a 0.6% rise in June.</p>\n<p>Major non-retail companies releasing results this week include Pandora and&nbsp;Krispy Kreme&nbsp;on Tuesday, followed by a busy Wednesday:Nvidia,Tencent Holdings,CiscoSystems,Analog Devices,and&nbsp;Lumentum Holdings&nbsp;all report.Applied Materials&nbsp;goes on Thursday and Deere closes the week on Friday.</p>\n<p>Economic data out this week include several housing-market metrics:&nbsp;The National Association of Home Builders’ NAHB/Wells Fargo Housing Market Index for August on Tuesday and the Census Bureau’s new residential construction report for July on Wednesday.</p>\n<p>Also on Wednesday, the&nbsp;Federal Reserve’s monetary policy committee releases the minutes from its last meeting in late July. Then, the&nbsp;Conference Board publishes its Leading Economic Index for July on Thursday.</p>\n<p><b>Monday 8/16</b></p>\n<p>Tencent Music Entertainment Group,Tokyo Electron,and&nbsp;Clear Secure&nbsp;are among the companies holding earnings conference calls.</p>\n<p><b>The Federal Reserve</b>&nbsp;Bank of New York releases its Empire State Manufacturing Survey for August. The consensus estimate is for a 26.5 reading. That compares with a record high of 43.0 in July, when the general business conditions index rose 26 points.</p>\n<p><b>Tuesday 8/17</b></p>\n<p>BHP, Walmart, Home Depot,Agilent Technologies,Pandora, and Krispy Kreme are among the companies hosting earnings conference calls.</p>\n<p>America’s Car-Mart,Jack Henry &amp; Associates,and&nbsp;La-Z-Boy&nbsp;report financial results after the market closes and will hold earnings calls the following morning, Aug. 18.</p>\n<p><b>The Federal Reserve</b>&nbsp;releases capacity utilization in the industrial sector for July. Consensus calls for a 75.7% reading, little changed from June’s 75.4% reading. Industrial production is seen rising 0.5% from June’s 0.4% seasonally adjusted increase.</p>\n<p><b>The National Association</b>&nbsp;of Home Builders releases its NAHB/Wells Fargo Housing Market Index for August. Economists forecast an 80 reading, the same as in July. The index is down from its all-time high of 90 set in November.</p>\n<p><b>Federal Reserve Board</b>&nbsp;Chairman Jay Powell will host a virtual town hall with educators and students.</p>\n<p><b>The Census Bureau reports</b>&nbsp;retail sales data for July. Expectations are for a 0.3% seasonally adjusted month-over-month decrease, following a 0.6% rise in June. Excluding autos, spending is seen rising 0.2%, compared with a 1.3% rise in the previous month.</p>\n<p><b>Wednesday 8/18</b></p>\n<p><b>The Federal Open Market</b>&nbsp;Committee releases the minutes from its late-July monetary-policy meeting.</p>\n<p>Cisco Systems, Lowe’s, Target, TJX, Tencent Holdings,Brinker International,Analog Devices,Synopsys,Lumentum Holdings, and Nvidia host earnings conference calls.</p>\n<p><b>The Census Bureau’s</b>new residential construction report for July is expected to show the seasonally adjusted annual rate of housing starts at 1.610 million, down from June’s 1.643 million. Housing starts hit a postpandemic peak of 1.73 million in March.</p>\n<p><b>Thursday 8/19</b></p>\n<p>BJ’s Wholesale,<b>L Brands</b>, Applied Materials,Ross Stores,Estée Lauder,Kohl’s, Macy’s,Performance Food Group,Petco Health and Wellness,and Farfetch host earnings conference calls.</p>\n<p><b>The Conference Board</b>releases its Leading Economic Index for July. The LEI is expected to increase 0.7% month over month, after gaining 0.7% in June.</p>\n<p><b>Friday 8/20</b></p>\n<p>Deere and Foot Locker host conference calls to discuss financial results.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia, Tencent,Walmart, Target and Other Stocks to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia, Tencent,Walmart, Target and Other Stocks to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-16 06:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-to-watch-this-week-51629054047?mod=hp_LEAD_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s the late innings of second-quarter earnings season, with retailers ready to step up to the plate. Walmart and Home Depot report on Tuesday, followed by Lowe’s, Target, and TJX on Wednesday. Kohl’...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-to-watch-this-week-51629054047?mod=hp_LEAD_2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WMT":"沃尔玛","TME":"腾讯音乐",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","TGT":"塔吉特","NVDA":"英伟达"},"source_url":"https://www.barrons.com/articles/stocks-to-watch-this-week-51629054047?mod=hp_LEAD_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129589874","content_text":"It’s the late innings of second-quarter earnings season, with retailers ready to step up to the plate. Walmart and Home Depot report on Tuesday, followed by Lowe’s, Target, and TJX on Wednesday. Kohl’s, Macy’s, BJ’s Wholesale, and L Brands are Thursday’s retail highlights, then Foot Locker closes the week on Friday.\nThe Census Bureau’s July retail sales data for July is also out this week, on Tuesday. Economists on average are forecasting a 0.2% seasonally adjusted increase last month, after a 0.6% rise in June.\nMajor non-retail companies releasing results this week include Pandora and Krispy Kreme on Tuesday, followed by a busy Wednesday:Nvidia,Tencent Holdings,CiscoSystems,Analog Devices,and Lumentum Holdings all report.Applied Materials goes on Thursday and Deere closes the week on Friday.\nEconomic data out this week include several housing-market metrics: The National Association of Home Builders’ NAHB/Wells Fargo Housing Market Index for August on Tuesday and the Census Bureau’s new residential construction report for July on Wednesday.\nAlso on Wednesday, the Federal Reserve’s monetary policy committee releases the minutes from its last meeting in late July. Then, the Conference Board publishes its Leading Economic Index for July on Thursday.\nMonday 8/16\nTencent Music Entertainment Group,Tokyo Electron,and Clear Secure are among the companies holding earnings conference calls.\nThe Federal Reserve Bank of New York releases its Empire State Manufacturing Survey for August. The consensus estimate is for a 26.5 reading. That compares with a record high of 43.0 in July, when the general business conditions index rose 26 points.\nTuesday 8/17\nBHP, Walmart, Home Depot,Agilent Technologies,Pandora, and Krispy Kreme are among the companies hosting earnings conference calls.\nAmerica’s Car-Mart,Jack Henry & Associates,and La-Z-Boy report financial results after the market closes and will hold earnings calls the following morning, Aug. 18.\nThe Federal Reserve releases capacity utilization in the industrial sector for July. Consensus calls for a 75.7% reading, little changed from June’s 75.4% reading. Industrial production is seen rising 0.5% from June’s 0.4% seasonally adjusted increase.\nThe National Association of Home Builders releases its NAHB/Wells Fargo Housing Market Index for August. Economists forecast an 80 reading, the same as in July. The index is down from its all-time high of 90 set in November.\nFederal Reserve Board Chairman Jay Powell will host a virtual town hall with educators and students.\nThe Census Bureau reports retail sales data for July. Expectations are for a 0.3% seasonally adjusted month-over-month decrease, following a 0.6% rise in June. Excluding autos, spending is seen rising 0.2%, compared with a 1.3% rise in the previous month.\nWednesday 8/18\nThe Federal Open Market Committee releases the minutes from its late-July monetary-policy meeting.\nCisco Systems, Lowe’s, Target, TJX, Tencent Holdings,Brinker International,Analog Devices,Synopsys,Lumentum Holdings, and Nvidia host earnings conference calls.\nThe Census Bureau’snew residential construction report for July is expected to show the seasonally adjusted annual rate of housing starts at 1.610 million, down from June’s 1.643 million. Housing starts hit a postpandemic peak of 1.73 million in March.\nThursday 8/19\nBJ’s Wholesale,L Brands, Applied Materials,Ross Stores,Estée Lauder,Kohl’s, Macy’s,Performance Food Group,Petco Health and Wellness,and Farfetch host earnings conference calls.\nThe Conference Boardreleases its Leading Economic Index for July. The LEI is expected to increase 0.7% month over month, after gaining 0.7% in June.\nFriday 8/20\nDeere and Foot Locker host conference calls to discuss financial results.","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":800175234,"gmtCreate":1627288624128,"gmtModify":1633766492980,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/800175234","repostId":"2154934710","repostType":4,"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":116584895,"gmtCreate":1622812318017,"gmtModify":1634097787014,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Should buy?","listText":"Should buy?","text":"Should buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/116584895","repostId":"1169305457","repostType":4,"repost":{"id":"1169305457","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1622793856,"share":"https://www.laohu8.com/m/news/1169305457?lang=&edition=full","pubTime":"2021-06-04 16:04","market":"us","language":"en","title":"AMC shares tanked another 5% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1169305457","media":"Tiger Newspress","summary":"AMC shares tanked another 5% in premarket trading.AMC Entertainment shares plunged 18% on Thursday f","content":"<p>AMC shares tanked another&nbsp;5% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/651c70ab98e89bf8e6705480ef126728\" tg-width=\"909\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p><p>AMC Entertainment&nbsp;shares plunged&nbsp;18% on Thursday&nbsp;following a stock sale announcement.</p><p>AMC Entertainment Holdings Inc.&nbsp;is asking investors to authorize an additional 25 million new shares,aiming tocapitalize on a rally that has sent the stock of the ailing movie-theater chain up about 2,300% this year.</p><p>The proposal announced Thursday in a filing will be put to a vote at the company’s July 29 annual meeting. The equity today would be valued at $1.3 billion, though the company promised not to issue the new shares in 2021.</p><p>“To successfully navigate the road ahead, we seek to assemble all of the financial tools that might help us,” Chief Executive Officer Adam Aron said in a statement. “An important tool for any company is having shares available to issue.”</p><p>The request is perhaps unsurprising for a company that’s become the king of meme stocks, at the heart of a frenzy of online traders determine to pump up its valuation.</p><p>Still, it’s a major retreat from a request earlier this year to authorize 500 million new shares. That proposal was originally up for a vote in May, but the annual meeting was postponed and the request withdrawn after it became clear investors would shoot it down.</p><p>Aron said in April the struggling company could issue about 43 million new shares. With sales of new stock totaling more than $800 million just this week, AMC has now completed nearly all of that authorization, according to the filing.</p><p>In a YouTube interview Thursday, Aron said proceeds from another equity sale, if approved, would be used to reduce debt, help the company negotiate with landlords who are owed $400 million, and to chase acquisitions “hard.”</p><p>”It’s our view that we’re strengthening the company,” he said. “We’re not hurting the company.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC shares tanked another 5% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC shares tanked another 5% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-04 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AMC shares tanked another&nbsp;5% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/651c70ab98e89bf8e6705480ef126728\" tg-width=\"909\" tg-height=\"663\" referrerpolicy=\"no-referrer\"></p><p>AMC Entertainment&nbsp;shares plunged&nbsp;18% on Thursday&nbsp;following a stock sale announcement.</p><p>AMC Entertainment Holdings Inc.&nbsp;is asking investors to authorize an additional 25 million new shares,aiming tocapitalize on a rally that has sent the stock of the ailing movie-theater chain up about 2,300% this year.</p><p>The proposal announced Thursday in a filing will be put to a vote at the company’s July 29 annual meeting. The equity today would be valued at $1.3 billion, though the company promised not to issue the new shares in 2021.</p><p>“To successfully navigate the road ahead, we seek to assemble all of the financial tools that might help us,” Chief Executive Officer Adam Aron said in a statement. “An important tool for any company is having shares available to issue.”</p><p>The request is perhaps unsurprising for a company that’s become the king of meme stocks, at the heart of a frenzy of online traders determine to pump up its valuation.</p><p>Still, it’s a major retreat from a request earlier this year to authorize 500 million new shares. That proposal was originally up for a vote in May, but the annual meeting was postponed and the request withdrawn after it became clear investors would shoot it down.</p><p>Aron said in April the struggling company could issue about 43 million new shares. With sales of new stock totaling more than $800 million just this week, AMC has now completed nearly all of that authorization, according to the filing.</p><p>In a YouTube interview Thursday, Aron said proceeds from another equity sale, if approved, would be used to reduce debt, help the company negotiate with landlords who are owed $400 million, and to chase acquisitions “hard.”</p><p>”It’s our view that we’re strengthening the company,” he said. “We’re not hurting the company.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169305457","content_text":"AMC shares tanked another 5% in premarket trading.AMC Entertainment shares plunged 18% on Thursday following a stock sale announcement.AMC Entertainment Holdings Inc. is asking investors to authorize an additional 25 million new shares,aiming tocapitalize on a rally that has sent the stock of the ailing movie-theater chain up about 2,300% this year.The proposal announced Thursday in a filing will be put to a vote at the company’s July 29 annual meeting. The equity today would be valued at $1.3 billion, though the company promised not to issue the new shares in 2021.“To successfully navigate the road ahead, we seek to assemble all of the financial tools that might help us,” Chief Executive Officer Adam Aron said in a statement. “An important tool for any company is having shares available to issue.”The request is perhaps unsurprising for a company that’s become the king of meme stocks, at the heart of a frenzy of online traders determine to pump up its valuation.Still, it’s a major retreat from a request earlier this year to authorize 500 million new shares. That proposal was originally up for a vote in May, but the annual meeting was postponed and the request withdrawn after it became clear investors would shoot it down.Aron said in April the struggling company could issue about 43 million new shares. With sales of new stock totaling more than $800 million just this week, AMC has now completed nearly all of that authorization, according to the filing.In a YouTube interview Thursday, Aron said proceeds from another equity sale, if approved, would be used to reduce debt, help the company negotiate with landlords who are owed $400 million, and to chase acquisitions “hard.””It’s our view that we’re strengthening the company,” he said. “We’re not hurting the company.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":864125293,"gmtCreate":1633076360568,"gmtModify":1633076361565,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864125293","repostId":"2172951249","repostType":4,"repost":{"id":"2172951249","kind":"news","pubTimestamp":1633063493,"share":"https://www.laohu8.com/m/news/2172951249?lang=&edition=full","pubTime":"2021-10-01 12:44","market":"us","language":"en","title":"Billionaire Bill Ackman is smoking 'mentor' Warren Buffett with these income stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2172951249","media":"MoneyWise","summary":"Dividend stocks might look boring, but they can provide exciting returns.\nJust ask famed activist in","content":"<p><img src=\"https://static.tigerbbs.com/968262da7f9e673173261c3b2753bbcd\" tg-width=\"1800\" tg-height=\"800\" referrerpolicy=\"no-referrer\"></p>\n<p>Dividend stocks might look boring, but they can provide exciting returns.</p>\n<p>Just ask famed activist investor and self-proclaimed Warren Buffett acolyte Bill Ackman.</p>\n<p>His hedge fund Pershing Square Holdings has delivered annualized total returns of more than 30% over the last three years, substantially outperforming the S&amp;P 500 and even Buffett’s own Berkshire Hathaway.</p>\n<p>And he did it largely by owning dividend stocks.</p>\n<p>According to Pershing’s latest 13F filing with the Securities Exchange Commission, nearly 60% of its holdings by market value are invested in dividend stocks.</p>\n<p>Let’s take a look at three stocks in Ackman’s portfolio that regulary dish out cash to investors — <a href=\"https://laohu8.com/S/AONE.U\">one</a> of them could be worth buying with your spare change.</p>\n<h2><a href=\"https://laohu8.com/S/QSR\">Restaurant Brands International Inc</a> (QSR)</h2>\n<p><img src=\"https://static.tigerbbs.com/ab0e3bda7c2635779ea2e4385b71b4f5\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">Tony Prato/Shutterstock</p>\n<p>Leading off the list is Restaurant Brands International, a fast-food holding company formed in 2014 by the merger between Burger King and Canadian coffee chain <a href=\"https://laohu8.com/S/THI\">Tim Hortons</a>.</p>\n<p>In 2017, the company added Popeyes Louisiana Kitchen to its portfolio.</p>\n<p>Like most restaurant stocks, Restaurant Brands shares tumbled during the pandemic-induced market sell-off in early 2020. But the stock has since made a strong recovery.</p>\n<p>That rebound is backed by substantial improvements in the company’s business. According to the latest earnings report, same-store sales — a key measure of a retailer’s health — increased 27.6%.</p>\n<p>Adjusted earnings came in at $0.77 per share for the quarter, more than double the $0.33 per share it earned in the year-ago period. The amount also covered the company’s quarterly dividend payment of $0.53 per share with ease.</p>\n<p>Restaurant Brands is offering a healthy annual dividend yield of 3.4%, which is a return investors can earn even if they're investing with spare nickels and dimes.</p>\n<p>For comparison, that’s a higher yield than fast-food restaurant giants McDonald’s (2.26%), Starbucks (1.6%), and Yum! Brands (1.6%).</p>\n<h2>Lowe’s Companies Inc (LOW)</h2>\n<p><img src=\"https://static.tigerbbs.com/9156dee5d6fe15d87a22b5b32ec030c4\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">Ken Wolter/Shutterstock</p>\n<p>Lowe’s is Bill Ackman’s largest holding by market value, and the position has served the billionaire investor quite well.</p>\n<p>Shares of the home improvement retail giant are up 29% year to date. The S&amp;P 500 has returned 16% over the same period.</p>\n<p>What’s more impressive than Lowe’s near-term stock price performance is how the company’s dividend has grown over the years.</p>\n<p>The economy moves in cycles, but Lowe’s payout has only gone up. In fact, the company has increased its payout to shareholders every year for the past 59 years.</p>\n<p>Decades of dividend hikes has brought Lowe’s quarterly dividend to $0.80 per share, translating to an annual yield of 1.5%.</p>\n<p>Note that its competitors are also dividend-paying companies: Home Depot yields 2.0%, Target pays 1.5%, while Walmart offers an annual yield of 1.6%.</p>\n<p>Due to Lowe’s rally over the past year, its shares now trade at over $200. But you can get a piece of the company using a popular stock trading app that allows you to buy fractions of shares with as much money as you’re willing to spend.</p>\n<h2>Agilent Technologies Inc (A)</h2>\n<p><img src=\"https://static.tigerbbs.com/bb79764fc5df837d32b32e674c6d4ec9\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">Elnur/Shutterstock</p>\n<p>Agilent isn’t a household name, but within its own industry, the company is a force to be reckoned with.</p>\n<p>Agilent provides bio-analyitical and electronic measurement solutions to a wide variety of industries including communications, life sciences, and chemical analysis.</p>\n<p>Headquartered in Santa Clara, Calif., the company’s products are used by 265,000 labs around the world. In Agilent’s fiscal 2020, it brought in $5.34 billion of total revenue.</p>\n<p>And in the most recent quarter, revenue grew 26% year-over-year to $1.59 billion.</p>\n<p>Given this kind of performance, you’d think Agilent shares would be soaring. But while the stock has returned a solid 60% over the past year, it has pulled back about 10% since the peak in early September.</p>\n<p>On the dividend front, Agilent offers an annual yield of 0.5%, which may not seem like much. But the company has an excellent track record when it comes to returning cash to investors: Since 2014, Agilent’s per share quarterly payout has increased by 106%.</p>\n<h2>Rental income stream?</h2>\n<p>The neat thing with dividend stocks is that they provide a way for investors to earn a steady income stream regardless of what the economy is doing.</p>\n<p>Of course, you don’t have to limit yourself to the stock market to do that.</p>\n<p>For instance, one investing service makes it possible to lock in a steady rental income stream by investing in premium real estate properties — from commercial developments in LA to residential buildings in NYC.</p>\n<p>You’ll gain exposure to high-end properties that big-time real estate moguls usually have access to, and you’ll receive regular payouts in the form of quarterly dividend distributions.</p>\n<p><i>This article provides information only and should not be construed as advice. It is provided without warranty of any kind.</i></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Billionaire Bill Ackman is smoking 'mentor' Warren Buffett with these income stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBillionaire Bill Ackman is smoking 'mentor' Warren Buffett with these income stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 12:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/billionaire-bill-ackman-smoking-mentor-201900070.html><strong>MoneyWise</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dividend stocks might look boring, but they can provide exciting returns.\nJust ask famed activist investor and self-proclaimed Warren Buffett acolyte Bill Ackman.\nHis hedge fund Pershing Square ...</p>\n\n<a href=\"https://finance.yahoo.com/news/billionaire-bill-ackman-smoking-mentor-201900070.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WMT":"沃尔玛","YUM":"百胜餐饮集团","TGT":"塔吉特","QSR":"餐饮品牌国际","MCD":"麦当劳","LOW":"劳氏","SBUX":"星巴克","HD":"家得宝","A":"安捷伦科技"},"source_url":"https://finance.yahoo.com/news/billionaire-bill-ackman-smoking-mentor-201900070.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172951249","content_text":"Dividend stocks might look boring, but they can provide exciting returns.\nJust ask famed activist investor and self-proclaimed Warren Buffett acolyte Bill Ackman.\nHis hedge fund Pershing Square Holdings has delivered annualized total returns of more than 30% over the last three years, substantially outperforming the S&P 500 and even Buffett’s own Berkshire Hathaway.\nAnd he did it largely by owning dividend stocks.\nAccording to Pershing’s latest 13F filing with the Securities Exchange Commission, nearly 60% of its holdings by market value are invested in dividend stocks.\nLet’s take a look at three stocks in Ackman’s portfolio that regulary dish out cash to investors — one of them could be worth buying with your spare change.\nRestaurant Brands International Inc (QSR)\nTony Prato/Shutterstock\nLeading off the list is Restaurant Brands International, a fast-food holding company formed in 2014 by the merger between Burger King and Canadian coffee chain Tim Hortons.\nIn 2017, the company added Popeyes Louisiana Kitchen to its portfolio.\nLike most restaurant stocks, Restaurant Brands shares tumbled during the pandemic-induced market sell-off in early 2020. But the stock has since made a strong recovery.\nThat rebound is backed by substantial improvements in the company’s business. According to the latest earnings report, same-store sales — a key measure of a retailer’s health — increased 27.6%.\nAdjusted earnings came in at $0.77 per share for the quarter, more than double the $0.33 per share it earned in the year-ago period. The amount also covered the company’s quarterly dividend payment of $0.53 per share with ease.\nRestaurant Brands is offering a healthy annual dividend yield of 3.4%, which is a return investors can earn even if they're investing with spare nickels and dimes.\nFor comparison, that’s a higher yield than fast-food restaurant giants McDonald’s (2.26%), Starbucks (1.6%), and Yum! Brands (1.6%).\nLowe’s Companies Inc (LOW)\nKen Wolter/Shutterstock\nLowe’s is Bill Ackman’s largest holding by market value, and the position has served the billionaire investor quite well.\nShares of the home improvement retail giant are up 29% year to date. The S&P 500 has returned 16% over the same period.\nWhat’s more impressive than Lowe’s near-term stock price performance is how the company’s dividend has grown over the years.\nThe economy moves in cycles, but Lowe’s payout has only gone up. In fact, the company has increased its payout to shareholders every year for the past 59 years.\nDecades of dividend hikes has brought Lowe’s quarterly dividend to $0.80 per share, translating to an annual yield of 1.5%.\nNote that its competitors are also dividend-paying companies: Home Depot yields 2.0%, Target pays 1.5%, while Walmart offers an annual yield of 1.6%.\nDue to Lowe’s rally over the past year, its shares now trade at over $200. But you can get a piece of the company using a popular stock trading app that allows you to buy fractions of shares with as much money as you’re willing to spend.\nAgilent Technologies Inc (A)\nElnur/Shutterstock\nAgilent isn’t a household name, but within its own industry, the company is a force to be reckoned with.\nAgilent provides bio-analyitical and electronic measurement solutions to a wide variety of industries including communications, life sciences, and chemical analysis.\nHeadquartered in Santa Clara, Calif., the company’s products are used by 265,000 labs around the world. In Agilent’s fiscal 2020, it brought in $5.34 billion of total revenue.\nAnd in the most recent quarter, revenue grew 26% year-over-year to $1.59 billion.\nGiven this kind of performance, you’d think Agilent shares would be soaring. But while the stock has returned a solid 60% over the past year, it has pulled back about 10% since the peak in early September.\nOn the dividend front, Agilent offers an annual yield of 0.5%, which may not seem like much. But the company has an excellent track record when it comes to returning cash to investors: Since 2014, Agilent’s per share quarterly payout has increased by 106%.\nRental income stream?\nThe neat thing with dividend stocks is that they provide a way for investors to earn a steady income stream regardless of what the economy is doing.\nOf course, you don’t have to limit yourself to the stock market to do that.\nFor instance, one investing service makes it possible to lock in a steady rental income stream by investing in premium real estate properties — from commercial developments in LA to residential buildings in NYC.\nYou’ll gain exposure to high-end properties that big-time real estate moguls usually have access to, and you’ll receive regular payouts in the form of quarterly dividend distributions.\nThis article provides information only and should not be construed as advice. It is provided without warranty of any kind.","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690605469,"gmtCreate":1639660809729,"gmtModify":1639660810880,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690605469","repostId":"1191683541","repostType":4,"repost":{"id":"1191683541","kind":"news","pubTimestamp":1639658241,"share":"https://www.laohu8.com/m/news/1191683541?lang=&edition=full","pubTime":"2021-12-16 20:37","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1191683541","media":"Benzinga","summary":"Stifel cut the price target on Under Armour, Inc.. from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.RBC Capital lowered the price target on Airbnb, Inc. from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.Morgan Stanley lowered DocuSign, Inc. price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.Barclays cut the price target on Aptiv PLC from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market","content":"<ul>\n <li>Stifel cut the price target on&nbsp;<b>Under Armour, Inc..</b>(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.</li>\n <li>RBC Capital lowered the price target on&nbsp;<b>Airbnb, Inc.</b>(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.</li>\n <li>Morgan Stanley cut&nbsp;<b>AT&amp;T Inc.</b>(NYSE:T) price target from $32 to $28. AT&amp;T shares rose 1.7% to $22.55 in pre-market trading.</li>\n <li>Morgan Stanley lowered&nbsp;<b>DocuSign, Inc.</b>(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.</li>\n <li>Barclays cut the price target on&nbsp;<b>Aptiv PLC</b>(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.</li>\n <li>Raymond James raised&nbsp;<b>The Progressive Corporation</b>(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Magna International Inc.</b>(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.</li>\n <li>B of A Securities reduced the price target for&nbsp;<b>Wayfair Inc.</b>(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. cut&nbsp;<b>IGM Biosciences, Inc.</b>(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.</li>\n <li>Needham cut&nbsp;<b>Medtronic plc</b>(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign","T":"美国电话电报","ABNB":"爱彼迎"},"source_url":"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191683541","content_text":"Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.\nMorgan Stanley cut AT&T Inc.(NYSE:T) price target from $32 to $28. AT&T shares rose 1.7% to $22.55 in pre-market trading.\nMorgan Stanley lowered DocuSign, Inc.(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.\nBarclays cut the price target on Aptiv PLC(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.\nRaymond James raised The Progressive Corporation(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.\nWells Fargo boosted the price target for Magna International Inc.(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.\nB of A Securities reduced the price target for Wayfair Inc.(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.\nHC Wainwright & Co. cut IGM Biosciences, Inc.(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.\nNeedham cut Medtronic plc(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604284528,"gmtCreate":1639403527473,"gmtModify":1639403980729,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604284528","repostId":"1101330061","repostType":4,"repost":{"id":"1101330061","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639402663,"share":"https://www.laohu8.com/m/news/1101330061?lang=&edition=full","pubTime":"2021-12-13 21:37","market":"us","language":"en","title":"Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI","url":"https://stock-news.laohu8.com/highlight/detail?id=1101330061","media":"Tiger Newspress","summary":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today ann","content":"<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VERU":"Veru Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101330061","content_text":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).\nENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605640297,"gmtCreate":1639160477225,"gmtModify":1639160478352,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605640297","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://www.laohu8.com/m/news/1133027099?lang=&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-11 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":751,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840566249,"gmtCreate":1635661104951,"gmtModify":1635661105328,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840566249","repostId":"2179226336","repostType":4,"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853243645,"gmtCreate":1634819063566,"gmtModify":1634819074078,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/853243645","repostId":"1192205953","repostType":4,"repost":{"id":"1192205953","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634818772,"share":"https://www.laohu8.com/m/news/1192205953?lang=&edition=full","pubTime":"2021-10-21 20:19","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1192205953","media":"Tiger Newspress","summary":"Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time ","content":"<p>Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time highs as a parade of strong earnings results helped buoy equity prices earlier this week.</p>\n<p><img src=\"https://static.tigerbbs.com/4be1cf44a88f742bce145b6a6868682f\" tg-width=\"286\" tg-height=\"117\" width=\"100%\" height=\"auto\">At 8:00 a.m. ET, Dow e-minis were&nbsp;down&nbsp;108&nbsp;points, or 0.3%, S&amp;P 500 e-minis were&nbsp;down&nbsp;13.75 points, or 0.3%, and Nasdaq 100 e-minis were down&nbsp;61&nbsp;points, or 0.4%.</p>\n<p>IBM&nbsp;slipped 4.7% after it missed market estimates for quarterly revenue as its managed infrastructure business suffered from a decline in orders.</p>\n<p>Tesla fell 1% in premarket trading as it said on Wednesday its upcoming factories and supply-chain headwinds would put pressure on its margins after it beat Wall Street expectations for third-quarter revenue.</p>\n<p>AT&amp;T rose 1% after the telecom operator's quarterly revenue and monthly phone bill paying subscriber additions beat market expectations.</p>\n<p>Dow gained 1.1% after it posted a more than a five-fold jump in third-quarter profit as economic recovery boosted prices for chemicals.</p>\n<p>In currencies,the euro was little changed at $1.1640,the British pound fell 0.1% to $1.3810,the Japanese yen rose 0.3% to 114.02 per dollar.</p>\n<p>In bonds,the yield on 10-year Treasuries was little changed at 1.66%,Germany’s 10-year yield advanced two basis points to -0.11%,Britain’s 10-year yield advanced four basis points to 1.18%.</p>\n<p>In commodities,West Texas Intermediate crude fell 0.8% to $82.75 a barrel,Gold futures were little changed.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-21 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time highs as a parade of strong earnings results helped buoy equity prices earlier this week.</p>\n<p><img src=\"https://static.tigerbbs.com/4be1cf44a88f742bce145b6a6868682f\" tg-width=\"286\" tg-height=\"117\" width=\"100%\" height=\"auto\">At 8:00 a.m. ET, Dow e-minis were&nbsp;down&nbsp;108&nbsp;points, or 0.3%, S&amp;P 500 e-minis were&nbsp;down&nbsp;13.75 points, or 0.3%, and Nasdaq 100 e-minis were down&nbsp;61&nbsp;points, or 0.4%.</p>\n<p>IBM&nbsp;slipped 4.7% after it missed market estimates for quarterly revenue as its managed infrastructure business suffered from a decline in orders.</p>\n<p>Tesla fell 1% in premarket trading as it said on Wednesday its upcoming factories and supply-chain headwinds would put pressure on its margins after it beat Wall Street expectations for third-quarter revenue.</p>\n<p>AT&amp;T rose 1% after the telecom operator's quarterly revenue and monthly phone bill paying subscriber additions beat market expectations.</p>\n<p>Dow gained 1.1% after it posted a more than a five-fold jump in third-quarter profit as economic recovery boosted prices for chemicals.</p>\n<p>In currencies,the euro was little changed at $1.1640,the British pound fell 0.1% to $1.3810,the Japanese yen rose 0.3% to 114.02 per dollar.</p>\n<p>In bonds,the yield on 10-year Treasuries was little changed at 1.66%,Germany’s 10-year yield advanced two basis points to -0.11%,Britain’s 10-year yield advanced four basis points to 1.18%.</p>\n<p>In commodities,West Texas Intermediate crude fell 0.8% to $82.75 a barrel,Gold futures were little changed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","IBM":"IBM","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192205953","content_text":"Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time highs as a parade of strong earnings results helped buoy equity prices earlier this week.\nAt 8:00 a.m. ET, Dow e-minis were down 108 points, or 0.3%, S&P 500 e-minis were down 13.75 points, or 0.3%, and Nasdaq 100 e-minis were down 61 points, or 0.4%.\nIBM slipped 4.7% after it missed market estimates for quarterly revenue as its managed infrastructure business suffered from a decline in orders.\nTesla fell 1% in premarket trading as it said on Wednesday its upcoming factories and supply-chain headwinds would put pressure on its margins after it beat Wall Street expectations for third-quarter revenue.\nAT&T rose 1% after the telecom operator's quarterly revenue and monthly phone bill paying subscriber additions beat market expectations.\nDow gained 1.1% after it posted a more than a five-fold jump in third-quarter profit as economic recovery boosted prices for chemicals.\nIn currencies,the euro was little changed at $1.1640,the British pound fell 0.1% to $1.3810,the Japanese yen rose 0.3% to 114.02 per dollar.\nIn bonds,the yield on 10-year Treasuries was little changed at 1.66%,Germany’s 10-year yield advanced two basis points to -0.11%,Britain’s 10-year yield advanced four basis points to 1.18%.\nIn commodities,West Texas Intermediate crude fell 0.8% to $82.75 a barrel,Gold futures were little changed.","news_type":1},"isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":817388967,"gmtCreate":1630907542459,"gmtModify":1631889057217,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/817388967","repostId":"1110543090","repostType":4,"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814314281,"gmtCreate":1630762960443,"gmtModify":1631891242354,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814314281","repostId":"1169514310","repostType":4,"repost":{"id":"1169514310","kind":"news","pubTimestamp":1630656896,"share":"https://www.laohu8.com/m/news/1169514310?lang=&edition=full","pubTime":"2021-09-03 16:14","market":"us","language":"en","title":"2 Good Reasons the Stock Market Isn’t Ready to Blow Up Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=1169514310","media":"Barron's","summary":"tocks have had an impressive year so far, but there are still four months before 2021 wraps up. So w","content":"<p>tocks have had an impressive year so far, but there are still four months before 2021 wraps up. So what’s ahead? A correction? More gains? Right now, it’s easier to make the case for the rally to just keep on going.</p>\n<p>First, though, it’s understandable why investors might be nervous.</p>\n<p>TheS&amp;P 500has gained about 21% year to date, far above the historical average annual return of about 10%. And in the first eight months, the index hasn’t had a pullback of more than 5%— a correction is defined as a 10% drawdown.</p>\n<p>Still, a good run needs something to stop it—likehigher corporate taxes,which the Biden administration supports. They could shave 5% or more off projected earnings estimates for S&amp;P 500 companies. Or persistent inflation, which could cause the Federal Reserve to rapidly reduce economic support. And there are a host of other catalysts, enough to push some analyststo forecast a retreat.</p>\n<p>But who knows how long Washington might take to put a new tax structure in place, or if lawmakers even will. Or what the deal is with inflation. There has been tapering talk for a few months now, and the Fed holds firm to its wait-and-see approach.</p>\n<p>So the nature of the market’s climb in the past couple of weeks seems to be the surest, strongest sign of what’s ahead. The S&amp;P 500 is up 3% since Aug. 18, the bottom of a brief and shallow drop.</p>\n<p>“[Market] internals improved last week,” writes&nbsp;Michael Gibbs, director of equity portfolio and technical strategy at Raymond James.</p>\n<p>First off, transaction volumes are improving.</p>\n<p>In late August, the daily number of shares traded on the&nbsp;SPDR S&amp;P 500 Exchange-Traded Fund Trust(SPY) has been about 54 million, according to FactSet. That’s above just under 50 million seen in the middle of the month.</p>\n<p>The upshot: When more market participants are transacting and they are bidding prices higher, it’s a vote of confidence in the market.</p>\n<p>Secondly, the rally has been broad-based—many stocks have participated. For example, almost 80% of stocks listed on the New York Stock Exchange have been gaining, according to Raymond James.</p>\n<p>The last time that metric hit such a high was November 2020. More stocks participating in the rally means the major indexes are less dependent on one group of stocks to move higher. Plus, witheconomically sensitive stocks on a run as well,it means investors are confident in sustained economic growth ahead.</p>\n<p>So more gains or a correction? We’ve made our case, but time will tell.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Good Reasons the Stock Market Isn’t Ready to Blow Up Yet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Good Reasons the Stock Market Isn’t Ready to Blow Up Yet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 16:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stock-market-outlook-crash-or-rally-51630526109?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>tocks have had an impressive year so far, but there are still four months before 2021 wraps up. So what’s ahead? A correction? More gains? Right now, it’s easier to make the case for the rally to just...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-outlook-crash-or-rally-51630526109?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/stock-market-outlook-crash-or-rally-51630526109?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169514310","content_text":"tocks have had an impressive year so far, but there are still four months before 2021 wraps up. So what’s ahead? A correction? More gains? Right now, it’s easier to make the case for the rally to just keep on going.\nFirst, though, it’s understandable why investors might be nervous.\nTheS&P 500has gained about 21% year to date, far above the historical average annual return of about 10%. And in the first eight months, the index hasn’t had a pullback of more than 5%— a correction is defined as a 10% drawdown.\nStill, a good run needs something to stop it—likehigher corporate taxes,which the Biden administration supports. They could shave 5% or more off projected earnings estimates for S&P 500 companies. Or persistent inflation, which could cause the Federal Reserve to rapidly reduce economic support. And there are a host of other catalysts, enough to push some analyststo forecast a retreat.\nBut who knows how long Washington might take to put a new tax structure in place, or if lawmakers even will. Or what the deal is with inflation. There has been tapering talk for a few months now, and the Fed holds firm to its wait-and-see approach.\nSo the nature of the market’s climb in the past couple of weeks seems to be the surest, strongest sign of what’s ahead. The S&P 500 is up 3% since Aug. 18, the bottom of a brief and shallow drop.\n“[Market] internals improved last week,” writes Michael Gibbs, director of equity portfolio and technical strategy at Raymond James.\nFirst off, transaction volumes are improving.\nIn late August, the daily number of shares traded on the SPDR S&P 500 Exchange-Traded Fund Trust(SPY) has been about 54 million, according to FactSet. That’s above just under 50 million seen in the middle of the month.\nThe upshot: When more market participants are transacting and they are bidding prices higher, it’s a vote of confidence in the market.\nSecondly, the rally has been broad-based—many stocks have participated. For example, almost 80% of stocks listed on the New York Stock Exchange have been gaining, according to Raymond James.\nThe last time that metric hit such a high was November 2020. More stocks participating in the rally means the major indexes are less dependent on one group of stocks to move higher. Plus, witheconomically sensitive stocks on a run as well,it means investors are confident in sustained economic growth ahead.\nSo more gains or a correction? We’ve made our case, but time will tell.","news_type":1},"isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812287285,"gmtCreate":1630590673047,"gmtModify":1631891242365,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812287285","repostId":"1108690074","repostType":4,"isVote":1,"tweetType":1,"viewCount":346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890109525,"gmtCreate":1628085539167,"gmtModify":1633753745172,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/890109525","repostId":"1108635314","repostType":4,"repost":{"id":"1108635314","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628084737,"share":"https://www.laohu8.com/m/news/1108635314?lang=&edition=full","pubTime":"2021-08-04 21:45","market":"us","language":"en","title":"AMD gained over 5% and reached record high","url":"https://stock-news.laohu8.com/highlight/detail?id=1108635314","media":"Tiger Newspress","summary":"(August 4) AMD gained over 5% and reached record high.","content":"<p>(August 4)&nbsp;<a href=\"https://laohu8.com/S/AMD\">AMD</a> gained over 5% and reached record high.</p>\n<p><img src=\"https://static.tigerbbs.com/8b23aa43d6e0816bc9aeaa95fc08fcd6\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMD gained over 5% and reached record high</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMD gained over 5% and reached record high\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-04 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(August 4)&nbsp;<a href=\"https://laohu8.com/S/AMD\">AMD</a> gained over 5% and reached record high.</p>\n<p><img src=\"https://static.tigerbbs.com/8b23aa43d6e0816bc9aeaa95fc08fcd6\" tg-width=\"837\" tg-height=\"558\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108635314","content_text":"(August 4) AMD gained over 5% and reached record high.","news_type":1},"isVote":1,"tweetType":1,"viewCount":121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141228897,"gmtCreate":1625876245119,"gmtModify":1633936553728,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Keep on hold? Any advice?","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Keep on hold? Any advice?","text":"$AMC Entertainment(AMC)$Keep on hold? Any advice?","images":[{"img":"https://static.tigerbbs.com/7f5a964972d7799ab932c087f5eac71f","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/141228897","isVote":1,"tweetType":1,"viewCount":652,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":112340149,"gmtCreate":1622853032981,"gmtModify":1634097423462,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584863771682470","idStr":"3584863771682470"},"themes":[],"htmlText":"Should buy","listText":"Should buy","text":"Should buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/112340149","repostId":"1154529120","repostType":4,"repost":{"id":"1154529120","kind":"news","pubTimestamp":1622810459,"share":"https://www.laohu8.com/m/news/1154529120?lang=&edition=full","pubTime":"2021-06-04 20:40","market":"us","language":"en","title":"Can Alibaba Stock Hit $500? If You Got Time, Yes","url":"https://stock-news.laohu8.com/highlight/detail?id=1154529120","media":"seekingalpha","summary":"Alibaba is a battleground stock where some see a lot of opportunities, while others see many risks.I believe that there are both opportunities and risks, but would see the prior outweighing the latter.In the long run, BABA has a chance of delivering strong gains for those that buy at the current, quite low, valuation.Since its IPO, Alibaba has seen strong share price gains, but it should also be mentioned that shares did peek in H2 2020, and have declined considerably since then:. Alibaba Group'","content":"<p><b>Summary</b></p>\n<ul>\n <li>Alibaba is a battleground stock where some see a lot of opportunities, while others see many risks.</li>\n <li>I believe that there are both opportunities and risks, but would see the prior outweighing the latter.</li>\n <li>In the long run, BABA has a chance of delivering strong gains for those that buy at the current, quite low, valuation.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/567d19950e6c8789ce2192b4503f0fa5\" tg-width=\"1536\" tg-height=\"653\" referrerpolicy=\"no-referrer\"><span>Photo by efetova/iStock via Getty Images</span></p>\n<p><b>Article Thesis</b></p>\n<p>Alibaba Group (BABA) is a leading global high-tech name that continues to generate attractive growth and that offers investors exposure to the high-growth Chinese consumer market. At the same time, through a range of ventures, Alibaba is also active in additional industries, such as cloud computing. Shares have declined considerably over the last couple of months, but I believe that the long-term potential is significant. I would not be surprised to see shares rise towards $500, although that will not happen in the near term.</p>\n<p><b>BABA Stock Price</b></p>\n<p>Since its IPO, Alibaba has seen strong share price gains, but it should also be mentioned that shares did peek in H2 2020, and have declined considerably since then:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8079eeb5384ea003fb3725d3cd1e877f\" tg-width=\"635\" tg-height=\"403\"><span>Data byYCharts</span></p>\n<p>Shares are now basically where they were one year ago, as the gains during summer 2020 have been erased when Ant Financial's IPO plans were stopped. The flat share price performance over the last year is somewhat surprising, though, as Alibaba continued to generate strong results in that time frame. During the last quarter, for example, Alibaba showcased a&nbsp;revenue growth rate of 64%, while revenue growth during the previous quarter was also very strong, at around 50%. This is not the only positive in Alibaba's earnings releases, however. The company also managed to grow its user count by 32 million during the most recent quarter alone, which equates to an annualized user growth rate of around 20%. This bodes well for future quarters, as more users on Alibaba's platform should translate into higher revenues. On top of that, the strong user growth shows that there is still growing demand for the shopping services that Alibaba's platforms offer -- the market is not saturated at all. Alibaba also managed to grow its EBITDA by 25% year over year, which is an attractive growth pace as well, and which was achieved despite growing investments in what management calls key growth areas. Income from operations, meanwhile, grew at an even faster pace, thanks to some operating leverage, rising by 48% year over year when adjusted for the fine that Alibaba had to pay during Q1. It makes, I believe, sense to back out this one-time item to get a clearer picture about Alibaba's underlying, \"core\" profitability during an average quarter.</p>\n<p>Alibaba Group's weak share price performance, relative to the broad market and other tech names, is thus not the result of weak operating performance, but rather a result of multiple compression, driven by weak investor sentiment due to China exposure and&nbsp;fears about regulation.</p>\n<p>At its current price of $220, BABA trades at a quite large discount compared to the current consensus analyst price target of $298. If Alibaba were to hit that, shares would gain 35%. Analyst price targets are usually issued with a 1-year time frame, thus, if the analyst community is correct, Alibaba could be a great investment. From a valuation standpoint, this price target doesn't seem outrageous at all, as $298 would equate to around 29x this year's expected net profits, or 23x next year's net earnings. The latter is likely the more telling one when we talk about a price target for summer 2022, i.e. 1 year from now.</p>\n<p><b>Can Alibaba Stock Hit $500?</b></p>\n<p>The answer to that question, I think, depends on your time frame. If you are looking at a 12-month window, then Alibaba will most likely not be able to hit $500. The ~$300 price target seems achievable, although that is, of course, also not guaranteed. If, however, we take a longer-term view, then $500 seems like a share price that BABA could hit eventually. Let's look at a couple of examples.</p>\n<p><i>- If Alibaba were to generate earnings per share of $20 at some point and traded at an earnings multiple of 25, then shares would trade at $500.</i></p>\n<p><i>- If Alibaba were to generate earnings per share of $25 and traded at a 20x earnings multiple, then shares would trade at $500.</i></p>\n<p><i>- If Alibaba were to generate earnings per share of $17 and traded at 29x its net profits, then shares would trade at (marginally below) $500.</i></p>\n<p>We see that there are many scenarios that could get us to a $500 share price for BABA, some of them more likely than others. Of course, the higher your target multiple, the lower the earnings that would be required. This, in turn, means that the price target can be hit sooner, as less cumulative earnings growth would be required. When we take a look at how Alibaba was valued in the past, we see that the longer-term median earnings multiples for BABA look like this:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dd2d42b7094deb394266d6410287c2e4\" tg-width=\"635\" tg-height=\"436\"><span>Data byYCharts</span></p>\n<p>At 30-40x net earnings, Alibaba was clearly trading at a massive premium relative to how shares are valued today (around 20x this year's earnings). I think that the current valuation is too low, but on the other hand, I do not expect Alibaba to trade at 30, 35, or even 40x net profits in coming years. Due to the growing scale of Alibaba, which makes it a little harder to maintain its excellent growth in coming years, shares will likely trade at a lower valuation in coming years, compared to how they were valued in the past.</p>\n<p>I still think that shares do have some valuation expansion potential from the current earnings multiple of around 21, thus let's assume that shares trade at 23x net profits in the future. This would still represent a massive discount versus the historic valuation, and also a substantial discount compared to how US-based high-tech mega-caps are valued -- Amazon (AMZN), for example, trades at 59x this year's earnings.</p>\n<p>If we want to get to a $500 share price for BABA using a 23x earnings multiple, then we get to earnings per share of $21.70 that Alibaba must generate. When could this be the case? In the following chart, we see EPS estimates for the current year, next year (CY 2022), and CY 2023:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6fcf78e0b071eff9753afbdcd96f751c\" tg-width=\"635\" tg-height=\"436\"><span>Data byYCharts</span></p>\n<p>If analysts are right, Alibaba will not get to earn $22 a share through 2023, and I think that is realistic. I do not see earnings per share rising by 100%+ between this year and 2023, either. From 2023, it would take another 43% increase in Alibaba's earnings per share to get to $21.70, which is our \"target EPS\" for a $500 share price.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7b4c351b4b5eb3328191ccaa9a3b776c\" tg-width=\"635\" tg-height=\"403\"><span>Data byYCharts</span></p>\n<p>Analysts are currently forecasting long-term EPS growth of around 27%, which would mean it would take Alibaba about 1.5 years to grow its EPS from $15.20 (2023 estimate) to our target of $21.70. Even if we assume that this is too optimistic and that growth will be just 20% in 2024 and 2025, EPS of $21.70 could be hit by the end of 2025. So, in other words, if Alibaba grows a little less than what analysts are forecasting right now, Alibaba could trade at $500 by the end of 2025 -- or 4.5 years from now. Note that this scenario does not require a high earnings multiple at all -- at 23x net profits, Alibaba wouldn't be expensive, I believe.</p>\n<p>We can get even more conservative and assume that the 2023 EPS estimate is 10% too high and that EPS will grow by just 17% a year in the years beyond 2023 (versus a long-term forecast of 27% a year by the analyst community). In that case, Alibaba would hit $21.70 in earnings per share in 2026, and shares would rise to $500 over the next 5.5 years. Even in this scenario, BABA wouldn't be a bad investment at all -- a 130% share price increase from the current level over the next 5.5 years would equate to annualized returns of 16%.</p>\n<p>So, to sum this section up, I'd say<i>yes, BABA can hit $500</i>-- but it will realistically take a couple of years. By the mid-2020s, this seems like a very achievable goal to me, although there are, of course, no guarantees.</p>\n<p><b>Is Alibaba Stock A Buy Or Sell Now?</b></p>\n<p>Alibaba Group is, I believe, a strong investment. The company generates strong growth, profits from multiple long-term macro trends, such as growing consumer spending in China, growing e-commerce market share, and cloud computing. There are, however, risks to consider: Alibaba is highly China-dependent, and in case the economic growth story in China ends, Alibaba would be hurt a lot. On top of that, Alibaba could be targeted again by regulators, although I personally think that it is not in China's best interest to hurt one of its highest-growth tech companies.</p>\n<p>For those that worry about these risks, Alibaba may not be the right choice, but for those that see Alibaba as a potentially very rewarding play on Chinese consumers, BABA could be a strong pick in a diversified portfolio. I belong to the latter group and thus rate the stock a buy at current valuations, expecting significant upside over the coming years. Depending on your risk tolerance and how you weigh the opportunities and threats of investing in Chinese companies, you may decide differently, however.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Alibaba Stock Hit $500? If You Got Time, Yes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Alibaba Stock Hit $500? If You Got Time, Yes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-04 20:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4432992-alibaba-stock-hit-500><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nAlibaba is a battleground stock where some see a lot of opportunities, while others see many risks.\nI believe that there are both opportunities and risks, but would see the prior outweighing ...</p>\n\n<a href=\"https://seekingalpha.com/article/4432992-alibaba-stock-hit-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09988":"阿里巴巴-W","BABA":"阿里巴巴"},"source_url":"https://seekingalpha.com/article/4432992-alibaba-stock-hit-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154529120","content_text":"Summary\n\nAlibaba is a battleground stock where some see a lot of opportunities, while others see many risks.\nI believe that there are both opportunities and risks, but would see the prior outweighing the latter.\nIn the long run, BABA has a chance of delivering strong gains for those that buy at the current, quite low, valuation.\n\nPhoto by efetova/iStock via Getty Images\nArticle Thesis\nAlibaba Group (BABA) is a leading global high-tech name that continues to generate attractive growth and that offers investors exposure to the high-growth Chinese consumer market. At the same time, through a range of ventures, Alibaba is also active in additional industries, such as cloud computing. Shares have declined considerably over the last couple of months, but I believe that the long-term potential is significant. I would not be surprised to see shares rise towards $500, although that will not happen in the near term.\nBABA Stock Price\nSince its IPO, Alibaba has seen strong share price gains, but it should also be mentioned that shares did peek in H2 2020, and have declined considerably since then:\nData byYCharts\nShares are now basically where they were one year ago, as the gains during summer 2020 have been erased when Ant Financial's IPO plans were stopped. The flat share price performance over the last year is somewhat surprising, though, as Alibaba continued to generate strong results in that time frame. During the last quarter, for example, Alibaba showcased a revenue growth rate of 64%, while revenue growth during the previous quarter was also very strong, at around 50%. This is not the only positive in Alibaba's earnings releases, however. The company also managed to grow its user count by 32 million during the most recent quarter alone, which equates to an annualized user growth rate of around 20%. This bodes well for future quarters, as more users on Alibaba's platform should translate into higher revenues. On top of that, the strong user growth shows that there is still growing demand for the shopping services that Alibaba's platforms offer -- the market is not saturated at all. Alibaba also managed to grow its EBITDA by 25% year over year, which is an attractive growth pace as well, and which was achieved despite growing investments in what management calls key growth areas. Income from operations, meanwhile, grew at an even faster pace, thanks to some operating leverage, rising by 48% year over year when adjusted for the fine that Alibaba had to pay during Q1. It makes, I believe, sense to back out this one-time item to get a clearer picture about Alibaba's underlying, \"core\" profitability during an average quarter.\nAlibaba Group's weak share price performance, relative to the broad market and other tech names, is thus not the result of weak operating performance, but rather a result of multiple compression, driven by weak investor sentiment due to China exposure and fears about regulation.\nAt its current price of $220, BABA trades at a quite large discount compared to the current consensus analyst price target of $298. If Alibaba were to hit that, shares would gain 35%. Analyst price targets are usually issued with a 1-year time frame, thus, if the analyst community is correct, Alibaba could be a great investment. From a valuation standpoint, this price target doesn't seem outrageous at all, as $298 would equate to around 29x this year's expected net profits, or 23x next year's net earnings. The latter is likely the more telling one when we talk about a price target for summer 2022, i.e. 1 year from now.\nCan Alibaba Stock Hit $500?\nThe answer to that question, I think, depends on your time frame. If you are looking at a 12-month window, then Alibaba will most likely not be able to hit $500. The ~$300 price target seems achievable, although that is, of course, also not guaranteed. If, however, we take a longer-term view, then $500 seems like a share price that BABA could hit eventually. Let's look at a couple of examples.\n- If Alibaba were to generate earnings per share of $20 at some point and traded at an earnings multiple of 25, then shares would trade at $500.\n- If Alibaba were to generate earnings per share of $25 and traded at a 20x earnings multiple, then shares would trade at $500.\n- If Alibaba were to generate earnings per share of $17 and traded at 29x its net profits, then shares would trade at (marginally below) $500.\nWe see that there are many scenarios that could get us to a $500 share price for BABA, some of them more likely than others. Of course, the higher your target multiple, the lower the earnings that would be required. This, in turn, means that the price target can be hit sooner, as less cumulative earnings growth would be required. When we take a look at how Alibaba was valued in the past, we see that the longer-term median earnings multiples for BABA look like this:\nData byYCharts\nAt 30-40x net earnings, Alibaba was clearly trading at a massive premium relative to how shares are valued today (around 20x this year's earnings). I think that the current valuation is too low, but on the other hand, I do not expect Alibaba to trade at 30, 35, or even 40x net profits in coming years. Due to the growing scale of Alibaba, which makes it a little harder to maintain its excellent growth in coming years, shares will likely trade at a lower valuation in coming years, compared to how they were valued in the past.\nI still think that shares do have some valuation expansion potential from the current earnings multiple of around 21, thus let's assume that shares trade at 23x net profits in the future. This would still represent a massive discount versus the historic valuation, and also a substantial discount compared to how US-based high-tech mega-caps are valued -- Amazon (AMZN), for example, trades at 59x this year's earnings.\nIf we want to get to a $500 share price for BABA using a 23x earnings multiple, then we get to earnings per share of $21.70 that Alibaba must generate. When could this be the case? In the following chart, we see EPS estimates for the current year, next year (CY 2022), and CY 2023:\nData byYCharts\nIf analysts are right, Alibaba will not get to earn $22 a share through 2023, and I think that is realistic. I do not see earnings per share rising by 100%+ between this year and 2023, either. From 2023, it would take another 43% increase in Alibaba's earnings per share to get to $21.70, which is our \"target EPS\" for a $500 share price.\nData byYCharts\nAnalysts are currently forecasting long-term EPS growth of around 27%, which would mean it would take Alibaba about 1.5 years to grow its EPS from $15.20 (2023 estimate) to our target of $21.70. Even if we assume that this is too optimistic and that growth will be just 20% in 2024 and 2025, EPS of $21.70 could be hit by the end of 2025. So, in other words, if Alibaba grows a little less than what analysts are forecasting right now, Alibaba could trade at $500 by the end of 2025 -- or 4.5 years from now. Note that this scenario does not require a high earnings multiple at all -- at 23x net profits, Alibaba wouldn't be expensive, I believe.\nWe can get even more conservative and assume that the 2023 EPS estimate is 10% too high and that EPS will grow by just 17% a year in the years beyond 2023 (versus a long-term forecast of 27% a year by the analyst community). In that case, Alibaba would hit $21.70 in earnings per share in 2026, and shares would rise to $500 over the next 5.5 years. Even in this scenario, BABA wouldn't be a bad investment at all -- a 130% share price increase from the current level over the next 5.5 years would equate to annualized returns of 16%.\nSo, to sum this section up, I'd sayyes, BABA can hit $500-- but it will realistically take a couple of years. By the mid-2020s, this seems like a very achievable goal to me, although there are, of course, no guarantees.\nIs Alibaba Stock A Buy Or Sell Now?\nAlibaba Group is, I believe, a strong investment. The company generates strong growth, profits from multiple long-term macro trends, such as growing consumer spending in China, growing e-commerce market share, and cloud computing. There are, however, risks to consider: Alibaba is highly China-dependent, and in case the economic growth story in China ends, Alibaba would be hurt a lot. On top of that, Alibaba could be targeted again by regulators, although I personally think that it is not in China's best interest to hurt one of its highest-growth tech companies.\nFor those that worry about these risks, Alibaba may not be the right choice, but for those that see Alibaba as a potentially very rewarding play on Chinese consumers, BABA could be a strong pick in a diversified portfolio. I belong to the latter group and thus rate the stock a buy at current valuations, expecting significant upside over the coming years. Depending on your risk tolerance and how you weigh the opportunities and threats of investing in Chinese companies, you may decide differently, however.","news_type":1},"isVote":1,"tweetType":1,"viewCount":254,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}